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Abstract 
Interactions between proteins govern cellular and the body’s states, including aberrant 
interactions found in diseases such as in cancers and infections. Small molecule drugs 
are not ideal in targeting these interactions as their size generally prevents efficient 
blocking of contacts over large surface areas. Antibodies and related biologics have seen 
clinical success in the past few decades and can block large surfaces but are typically 
limited to extracellular targets. Intermediate-size peptides have the potential to bridge this 
gap, with the ability to target large surface areas inside the cell. Peptide stapling, by 
chemically linking two or more amino acid residues, can confer affinity improvements, 
resistance to degradation, and better biological transport properties. As such, stapled 
peptides show promise as next-generation therapeutics. Unfortunately, existing methods 
to screen sequence and stapling locations suffer from numerous disadvantages including 
limited search space, lack of real-time monitoring of selections, and difficulty in 
incorporating the non-canonical amino acids used for amino acid stapling.  
In this dissertation, I describe my research on stapled peptide discovery with 
bacterial incorporation of non-canonical amino acids. To screen stapled peptides of the 
type desired, we incorporated azidohomoalanine (AHA) into surface displayed peptides, 
enabling an in situ ‘click’ chemistry reaction to bridge two turns of an alpha helical (i, i+7) 
amino acid library for directed evolution. Using the p53-MDM2 interaction as a model 
target, we developed peptides that block MDM2 degradation of the tumor suppressor 
  xiv 
protein p53, an interaction that is dysregulated in a sizeable fraction of cancers. We 
generated and displayed a stapled peptide library on the bacterial cell surface with fixed 
residues for stabilization and binding requirements, while randomizing the remaining 
amino acids. After multiple rounds of selection, clones were sequenced and 
characterized. The dissociation constants of the peptide-MDM2 interaction were 
measured on both the bacterial cell surface by flow cytometry and in solution by bio-layer 
interferometry. The highest affinity variant, named SPD-M6-V1 with sequence 
VCDFXCYWNDLXGY (dissociation constant = 1.8 nM; X = azidohomoalanine) was 
selected for structural characterization by NMR spectroscopy, revealing a bicyclic 
disulfide and double click-constrained peptide. Sequencing showed that peptides with two 
cysteines were highly enriched, further suggesting that the MDM2-binding conformation 
was enforced with a disulfide bond. In addition, SPD-M6-V1 was the most protease-
resistant peptide from the library that we tested.  
Next, we stapled the displayed peptide library with chemically distinct linkers and 
screened each library separately. We performed deep sequencing to better understand 
the relationship between amino acid sequence and linker identity in contributing to high 
affinity MDM2 binding. We found that both linker-specific and linker-agnostic (i.e. MDM2-
specific) mutations were enhanced. Finally, we developed a dual-channel, sequential 
labeling selection strategy to discriminate between high-display, low-affinity peptides and 
low-display, high-affinity peptides, two categories that would ordinarily overlap in a typical 
one-color screen in the absence of an independent display marker. In summary, this 
thesis develops the chemical tools to screen libraries of stabilized peptides on the 
  xv 
bacterial cell surface and applies these techniques to select stabilized alpha helices that 
disrupt the p53-MDM2 interaction.   
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Chapter I: Introduction and Background 
Abstract 
Proteins are the workhorses of the cell, and in the course of carrying out their functions, 
will generally interact with one or more of the same or different proteins. The variety in 
the twenty naturally occurring amino acids endows proteins with diverse structures, 
leading to a massive range of functions ranging from biological signal transduction, 
chemical transformations, and genetic material manipulation (and these non-exhaustive 
categories often overlap). Because of their role in nearly all cellular activities, protein-
protein interactions are viewed as attractive drug targets as the blocking or enhancing of 
these can in theory result in therapeutic effects for a range of different diseases, such as 
Spike1-ACE2 in viral entry and p53-MDM2 and Her2/Her family in cancers, among others. 
In practice however, even after decades of developing small molecule drugs, protein-
protein interactions remain elusive drug targets. Binding interfaces between proteins often 
lack deep pockets, precluding targeting by traditional small molecules whereas large 
proteins, such as antibodies, suffer from poor intracellular uptake due to their size. In 
between these two categories, stabilized alpha helical peptides can enter cells but can 
also disrupt large protein-protein interfaces. Additionally, over the past two decades, 
researchers have developed ways to incorporate additional chemical functionality into 
proteins by incorporating noncanonical amino acids (NCAAs). These additional 
reactivities can be used bio-orthogonally to site-specifically modify NCAA-incorporated 
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peptides for stabilization. Displaying these peptides on the surface of bacteria offers a 
potent strategy for evolving stapled peptides against a variety of interactions, including 
the p53-MDM2 interaction which we focus on in this dissertation. 
 
Stapled Peptides 
The majority of interfaces between interacting proteins include an alpha helix, the most 
common protein secondary structure motif1. An alpha helix consists of a right-handed 
spiral of amino acids maintained by backbone hydrogen bonding interactions and 
outward-facing side chains. Such interfaces have posed attractive drug targets due to 
their importance in virtually all diseases, in which inhibition, by blocking interactions, or 
activation, by triggering function, can result in therapeutic effects2. However, due to the 
large size of protein-protein interaction surface areas, small molecules have seen little 
success in drug development to target protein-protein interactions3. Small molecules are 
better suited towards targeting catalytic sites or deep (generally hydrophobic) pockets, 
whereas protein-protein interfaces are generally characterized by shallow grooves and 
many intermolecular interactions.  
Despite these difficulties, the past two decades have yielded some success with 
small molecule inhibitors of PPI with more than 40 PPIs having been targeted with small 
molecules4; however, only two molecules have seen FDA approval (the integrin binder 
tirofiban4 and the BCL-2 binder Venotoclax5). These developments have led to an 
understanding that binding to the full surface area of a PPI is not typically necessary and 
targeting an important hotspot of a few amino acids is sufficient. Approaches like 
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fragment-based discovery have been developed to target PPIs by screening a small 
library of diverse molecules smaller than 300 Da for any affinity at all (typically 0.1 – 10 
mM). These initial hits are improved by introducing functional groups to yield more potent 
inhibitors6. However, most small molecules that have entered clinical testing still only 
target smaller interfaces (250 – 900 Å2) in which the biological interaction involves amino 
acid sidechain interaction with a deep pocket. These include so-called inhibitors of 
apoptosis proteins (IAPs), several of which mimic the caspase-activating domain 
tetrapeptide motif of Smac (Ala-Val-Pro-Ile) and have shown single-digit nM potency7. 
Venetoclax (developed as ABT-199), a BH3 mimic that binds to BCL2, has been 
approved by the FDA for chronic lymphocytic leukemia (CLL)5. The previous iteration of 
this drug, navitoclax (ABT-263) caused dose-limiting thrombocytopenia in patients due to 
BCL-xL engagement, and developing of ABT-199 required rational structure-enabled 
design to bias binding against BCL-xL (Kd < 0.01 nM for BCL-2, 48 nM for BCL-xL)8. 
Venetoclax so far is the only example of an alpha-helix-in-groove small molecule mimic 
that has received FDA approval. While there have been several examples of deep pocket 
PPI inhibition (e.g. the integrin antagonists tirofiban and lifitegrast), interactions involving 
secondary and tertiary structures have been more recalcitrant to small molecule inhibition 
due to their large surface area9. 
Antibodies and antibody-based molecules have seen great success in today’s 
oncology and autoimmune disease drug landscape in binding to proteins to alter function. 
They can be developed against virtually any protein target with high specificity and affinity 
but their use in the laboratory is restricted to extracellular proteins or intracellular proteins 
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inside permeabilized cells10. Clinical use has been limited to extracellular targets like 
Her2, integrins, EGFR, interleukins, and immune checkpoint proteins as these very large 
biomolecules are unable to cross plasma membranes without significant modifications. 
Antibody-drug conjugates (ADCs), which consist of potent, small molecule drugs attached 
to antibodies, rely on the antibody portion for binding and internalization11 and have seen 
recent success in the clinic for both liquid and solid tumors12. Once internalized, the small 
molecule payload can cross endosomal or lysosomal membranes to engage with their 
targets, typically microtubules or DNA, to achieve tumor cell killing. Usage of ADCs is 
restricted to tumors containing extracellular target-expressing cells. Approaches to 
directly target cytoplasmic proteins with antibodies involve attachment of cell-penetrating 
peptides13 or DNA transfection14, both which have limited clinical utility at this point. A 
potent, G12D mutation-specific (Kd = 6 nM) inhibitor of the KRAS-BRAF interaction was 
developed, but as this was based on a Sso7d protein scaffold (7 KDa), transfection was 
required for cellular activity14. 
Smaller peptides, of the length of 10 to 30 amino acids, are more capable of 
entering cells and inhibiting protein-protein interactions15. A given candidate peptide, 
when unmodified, will generally show poorly defined secondary structure and thus exhibit 
weak binding to its target. Binding to a protein interface requires the peptide to adopt a 
particular configuration, which can contribute to an entropic penalty, as the need for pre-
organization reduces the number of possible states. This entropic penalty is often 
accompanied by a kinetic enthalpic penalty as well, as a disordered peptide in solution 
contains a large number of water-side chain and water-backbone hydrogen bonds, which 
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need to be broken in order to adopt the binding configuration16. The formation of 
intramolecular and peptide-protein hydrogen bonds and other intermolecular bonds can 
reduce the thermodynamic enthalpic cost of desolvation, but kinetic effects can dominate 
formation of the complex in vivo.  Indeed, simulations by Bairy and Wong showed that for 
targeting the extracellular receptor EGFR, a faster on-rate drug was more efficacious than 
a slower off-rate drug at the same Kd17. In contrast, lower off-rates will increase target 
engagement time, which is important for slower signaling complexes18. Thus, optimization 
of both on and off rates is dependent on the signaling kinetics of the target, location, and 
safety considerations. When the peptide is unbound, it can undergo loss of effectiveness, 
such as through protease degradation and pharmacokinetic clearance, and therefore 
tuning kinetic rates for maximum efficacy and safety profiles is important. 
Within the last decade or so, the field of chemical biology has developed stapled 
peptides between 10 and 40 amino acids in length that contain a covalent link between 
two side chains (Figure I - 1).  
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Figure I - 1. Common chemistries used in peptide stapling approaches.  
A) amide bond formation between a bis-amine linker and two acidic side chains. B) 
disulfide bond C) thiol bridging with a bis-alkylating linker D) ring-closing metathesis of 
two O-allylserine residues E) ring-closing metathesis of two all-hydrocarbon side chains 
F) double-click stapling between a bis-alkyne linker and two azido side chains. Figure 
adapted from Atangcho et al. (2018)16. 
 
Stapled peptides have demonstrated greatly improved stability in the presence of 
proteases and higher binding affinities, enabling longer circulation times and considerable 
therapeutic potential. They have been developed for a range of protein targets, including 
KRAS19, the transcription factor NOTCH20, the plasma protease kallikrein21, and MDM222. 
In the last case, the stapled peptide inhibitor ALRN-6924 is in clinical trials23 at the time 
of this writing.  
Despite all the progress in the field, intracellular entry continues to be challenging 
and is the rate-limiting step for peptide efficacy. The sub-nanomolar binding affinity (Kd) 
of the related ALRN-related ATSP-70412 molecule can be contrasted with the much 
higher hundreds-of-nanomolar cellular toxicity24 (Ki), which may indicate a significant 
barrier to entry for this molecule. Along with direct confirmation that stapled peptides 
exhibit sequence- and staple-dependent uptake25,26, the discrepancy between potent Kd 
values and modest cellular efficacy have motivated major efforts to understand and 
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improve uptake. Early cell culture efficacy studies with hydrocarbon-stapled peptides 
involved the use of serum-free media27, and it is now appreciated that serum can interfere 
with cellular entry and efficacy in a sequence and staple-specific manner2,25. Bird et al. 
developed a medium-throughput microscopy assay to test a few dozen point mutants and 
staple locations of a BIM-mimic helix for cellular entry. They found that the presence of 
too many hydrophobic and cationic residues in a stapled peptide led to off-target toxicity 
due to membrane disruption, and that staple placement and helicity were key to cellular 
uptake25. Microscopy, however, has its drawbacks, as it is often difficult to differentiate 
among endosomal, membrane-bound, and cytoplasmic localized peptide28. Hydrophilic 
molecules generally lack the ability to cross the lipophilic core of cell membranes, and 
rapid endocytosis and endosomal/lysosomal residualization can resemble cytoplasmic 
signal especially in low-resolution imaging. The HaloTag-based chloroalkane penetration 
assay (CAPA) involves treating HaloTag-transfected cells with a chloroalkane-derivatized 
molecule of interest26. A covalent bond is formed between the HaloTag protein and 
chloroalkane-tagged molecule and this can be assayed with a chase with a dye-
chloroalkane and quantified by microscopy or flow cytometry. When HaloTag is localized 
to the cytoplasm via a mitochondria-outer membrane anchoring peptide, CAPA measures 
cytoplasmic access. Nuclear and other localization sequences can be employed to 
measure molecule entry to various compartments26. In order to engage intracellular 
targets, the majority of which are cytoplasmic, the stapled peptide must cross the cellular 
membrane. CAPA, cytoplasmic fluorescence-correlation spectroscopy28, and cellular 
thermal shift assays29 can be used to measure peptide entry into the cytoplasm. 
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Double-click stabilized peptides (Figure I - 1) were developed to expand the 
peptide stapling repertoire30 and has permitted modular, bifunctional strategies to not only 
improve stability through covalent cross-linking but also other properties using chemically 
diverse linkers31, such as ones containing polyarginine motifs to improve cell 
permeability32 and fluorophore-conjugated ones for imaging applications33. Unlike 
cysteine bridging or lysine/carboxylic acid lactamization, double-click chemistry through 
incorporation of azide or alkyne bearing residues is bio-orthogonal: side-reactions with 
other residues on the same peptide do not readily occur, and in the case of peptide 
stabilization on the protein and other macromolecule-dense bacterial outer membrane34, 
interference is less likely. As discussed below, azide-containing amino acids can be 
readily incorporated into induced proteins in E. coli, unlike the olefin-bearing amino acids 
used in all hydrocarbon stapling. Antibody fragments have been successfully displayed 
and reacted on the surface of E. coli with noncanonical amino acids35, exhibiting fast 
kinetics amenable for a directed evolution approach. The necessity of Cu(I) catalysis in 
standard azide-alkyne cycloaddition results in high levels of toxicity in bacteria36, and 
regrowth of bacteria following screening can be challenging37. The strain-promoted Cu-
free methodology38 has the potential to be much less toxic, but requires a bulky 
cyclooctyne reaction partner. The dearth of reports of successful protein-protein inhibitors 
using a strain-promoted reaction (one good example has been reported by Lau et al39) 
led us to focus on the Cu(I) catalyzed reaction in this dissertation. 
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Noncanonical amino acid incorporation 
Solid phase peptide synthesis (SPPS), which involves the stepwise C- to N-terminal 
conjugation of amino acids, has long been used to incorporate noncanonical amino 
acids40 (NCAAs). The length of peptides amenable to SPPS is typically limited to 50 
amino acids, as small yield losses per step compound to result in large losses and low 
efficiencies. Native chemical ligation has been used to connect two peptides in vitro, 
potentially extending the range of SPPS to hundreds of amino acids41, but this can also 
be low-yielding and results in a cysteine residue at the junction, which many proteins 
cannot tolerate. Furthermore, many applications of NCAAs require ribosomal translation, 
such as for intracellular activity, directed evolution screens, and metabolism 
studies35,42,43. Thus, there has been a multi-decade effort to expand the protein code 
outside the 20 ribosomally-incorporated canonical amino acids to facilitate non-native 
intermolecular interactions, reactivity, and structure.  
Selenomethionine (SeMet), a naturally occurring amino acid typically incorporated 
into proteins at methionine codons (AUG), has been used in quantitative replacement of 
methionine residues in recombinant proteins44,45, aiding in x-ray crystallographic 
applications and reportedly improving crystal diffraction resolution46. Incorporation of 
SeMet is typically accomplished in a methionine-auxotrophic strain of E. coli in minimal 
media containing SeMet44 and induced proteins purified similarly to the unmodified 
protein. More recent developments in NCAA applications involve the incorporation of 
azide-containing amino acids for translational labeling in a cell- and species- specific 
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manner to analyze protein expression by reaction, selective pull-down, and mass 
spectrometry47.  
Ribosomal NCAA incorporation efforts can be broadly categorized into two 
approaches: 1. Codon replacement or reassignment and 2. The NCAA as a canonical 
amino acid surrogate. In the codon replacement strategy, amber suppression, in which 
the amber stop codon (UAG) on mRNA is translated to incorporate a NCAA in the 
ribosome is the most commonly used approach. UAG is the most rare stop codon in E. 
coli, being used in only 7% of genes and only 2-3% of essential genes48, making global 
reassignment of UAG codons feasible without severe growth impairment48. For desired 
“mistranslation” by the endogenous ribosome, the cell must have a cognate AUC tRNA 
and corresponding tRNA synthetase reactive with the NCAA. An exogenous 
tRNA/aminoacyl tRNA synthetase pair (tRNA-aaRS) has to be artificially evolved to be 
both highly efficient and have low cross-reactivity with undesired amino acids49. The 
Schultz group has developed several such tRNA/aaRS pairs using parts from the archaea 
M. jannaschii with directed evolution for specificity and reactivity50. In this scheme, a 
randomized library of aaRS mutants go through both positive and negative sorts to ensure 
that the aaRS acylates the cognate tRNA with the NCAA but does not acylate the tRNA 
with endogenous amino acids. This approach has been used to introduce a wide range 
of functionalities into proteins, including fluorescence51, glycosylation52, and reactive 
azide groups for directed evolution in phages53. 
In the surrogate-replacement strategy, similar to SeMet incorporation, other 
NCAAs can be introduced into ribosomally synthesized proteins in auxotrophic bacteria. 
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A methionine-replacement strategy was used to incorporate azidohomoalanine (AHA) in 
methionine auxotrophic E. coli by Link, Tirrell, and coworkers54 (Figure I - 2). Other met-
replacement NCAAs include azidoalanine, azidonorvaline, and azidonorleucine54, with 
AHA having by far the highest efficiency with >95% incorporation at AUG codons55. 
Directed evolution and mutation of methionyl-tRNA synthetases and aaRS 
overexpression can be used to improve protein yields and incorporation efficiency, 
especially of more recalcitrant amino acids like azidonorleucine56,57 and the NMR-active 
trifluoronorleucine58. Design and evolution of phenyl and tyrosyl synthetases have been 
carried out for the incorporation of aryl amino acids59, and these various mutant 
synthetases represent a versatile toolkit for the incorporation of NCAAs into proteins.  
 
Figure I - 2. Structures of azidohomoalanine (AHA), and methionine (met),  
top and bottom respectively showing structural similarity. In met auxotrophic E. coli, AHA 
can be incorporated at high efficiency at AUG codons by endogenous met tRNA 
synthetase. 
 
Directed evolution and bacterial surface display 
Adaptation to environments, including inter- and intra-species competition, has led to the 
diversity of all life on earth60. Evolutionary forces have been observed and harnessed in 
NH2
O
OH
N3
NH2
S
O
OH
  12 
the lab, both in organisms to evolve novel metabolic pathways61 and in the round-bottom 
flask to yield powerful new enzymes62. In the past few decades, random mutagenesis 
paired with x-ray and NMR structural data have been powerful tools for engineering 
proteins with improved and novel activities63. A homology modeling approach, followed 
by multiple rounds of computational docking, evolution, and testing led to the engineering 
of a transaminase for industrial production of sitagliptin at Codexis and Merck64. 
Display techniques have greatly advanced the development of therapeutics and 
research proteins, especially antibodies and antibody derivatives, with combinatorial 
library screening enabled by diverse display methods coupling genetic information to 
phenotype, allowing rapid selection of favorable DNA sequences. Surface display 
techniques have been used successfully for the development of very high affinity 
antibodies, ScFvs evolved against whole cells, epitope mapping65 or for immune 
presentation of antigens for vaccination66. This has been recently recognized by the Nobel 
Prize in Chemistry in 2018 awarded partially for phage display, in which proteins are fused 
to bacteriophages capable of infecting E. coli. This permits various selection schemes, 
such as biopanning. In this, phage particles, containing displaying diverse and 
randomized protein sequences fused to phage coat proteins, are passed over a surface 
that is functionalized with the target, usually another protein65, but can also be inorganic 
materials67. Unbound or weakly bound phages are washed away, and bound phages are 
re-screened and eventually used to infect E. coli or directly sequenced68. 
In yeast and bacterial systems, surface display broadly involves cloning a 
randomized sequence as a fusion to an outer membrane-localizing display scaffold, 
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typically Aga2 in yeast69, or an outer membrane protein in bacteria70. The randomized 
sequence can be generated by a variety of methods, commonly error-prone PCR for 
larger proteins and DNA assembly using randomized primers for shorter peptides. In the 
yeast Aga2 system and in bacteria outer membrane fusions, induction causes localization 
of the random library to the cell exterior, where derivatized target protein is added71,72. 
Cell surface techniques have several advantages over phage-based display as the cells’ 
larger size allows for fluorescence-activated cell sorting (FACS) for excellent control over 
sorting parameters like sorted numbers and stringency.  
Selection takes place by enrichment for cells bound to target protein, identified by 
fluorescence if the derivatization is a fluorophore, and carried out using FACS. For larger 
library sizes, where FACS is intractable, bead-based sorting methods can be carried out 
for a preliminary round of sorting, using streptavidin coated beads and a biotinylated 
target71. After several rounds of selection, tightly binding clones are sequenced, and 
consensus sequences identified. Further affinity maturation is often carried out involving 
random mutagenesis of specific residues to sample sequences not present in the original 
library73. This is beneficial, as even for libraries of small peptides of length 12 amino acids, 
the theoretical diversity is greater than 1015, which cannot be achieved in phage, bacterial 
or yeast display systems. Whereas yeast surface display is very flexible in the type of 
protein to be displayed, in that the Aga2 system can display small peptides as well as 
large mammalian proteins72, using a bacterial display system has advantages that make 
it preferable for the stabilized peptide display presented in this dissertation. As discussed 
in the preceding section, NCAA incorporation into E. coli proteins is facile54. The higher 
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transformation efficiency in E. coli enables library sizes approaching 1011 members, 
whereas yeast methods are limited to around 107 sequences 71. The cellular nature of 
bacteria enables quantitative, real-time sorting by flow (i.e., FACS), unlike phage 
systems, which use panning. Cytometry allows for cell-based methods to rapidly quantify 
and compare the binding affinities of many clones without resorting to time-consuming 
solid-phase peptide synthesis, enabling initial affinity characterization of many more 
clones than phage or bead-based methods. 
 
Figure I - 3. Beta barrel structure of eCPX (left) and histograms of expression. 
The structure shows free N- and C- termini, adapted from Rice et al. (2008)74. Flow 
cytometry histograms of non-induced vs. arabinose-induced E. coli expressing exenatide-
4 using the eCPX scaffold (right). Peptides were detected by anti-exendin-4 labeling 
followed by AlexaFluor647 anti-mouse secondary staining. Even the relatively tightly 
regulated araBAD promoter results in a more than order of magnitude spread in detected 
signal (104 – 105). 
 
The eCPX scaffold used in this research permits simultaneous display of both C- 
and N- terminal fusion peptides74 (Figure I - 3, left). Previous directed evolution work with 
bacterial surface display used loop insertion fusions, where randomized peptides were 
incorporated within an extracellular loop in a bacterial outer membrane protein (e.g. 
N
C
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OmpA, FliTrx). However these peptides showed poor binding outside the loop context, as 
the binding peptide conformation required the framework of the display scaffold71. The 
eCPX and related OmpX-based systems have been used for a wide range of bacterial 
applications, including as effectors for light-induced expression75 and to engineer 
protease resistant affinity scaffolds76. In an interesting variation of a typical evolution 
screen, Pantazes, Daugherty, and coworkers displayed a randomized peptide library with 
eCPX on the E. coli surface and incubated with the serum antibody repertoire77. Antibody-
bound peptides were sorted with MACS or FACS, and the resulting libraries deep 
sequenced. Peptide sequences that bound to antibodies from patients with autoimmune 
diseases could be compared with those from healthy control subjects to identify significant 
motifs. Patients with celiac disease had much higher levels of antibody specific to the 
QPEQPFXE sequence, which appears in wheat, barley, and rye antigens. The pairing of 
surface display and deep sequencing has the potential to uncover exciting new directions 
in peptide engineering and antibody epitope discovery. 
The ability to display peptides both on the C- and N- terminus in eCPX permits the 
use of a second epitope to enable quantitation of display level. Randomized peptide 
display at the N terminus of eCPX and tag display at the C-terminus (e.g. HA tag) should, 
in theory, enable display normalization. Even with robust promoter and expression 
systems, a population of bacteria can display varying numbers of peptide per cell 
spanning as much as an order of magnitude (Figure I - 3, right). One round of FACS 
selection could then potentially exclude a tightly binding clone that stochastically displays 
a lower number of peptides and include a weaker binder with a higher displayed number 
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of peptides. The tighter binding cell would have a higher ratio of target signal to scaffold 
signal than a weaker binding cell, and the gate for sorting can be drawn to capture tight 
binding sequences, regardless of display level. In summary, bacteria display libraries 
have enabled the directed evolution of peptide sequences as binders to various disease-
relevant targets. 
 
The MDM2-p53 interaction 
Due to its widespread dysregulation in many cancers, MDM2 (mouse double minute 2 
protein) has posed as an attractive target for drug development. Despite this, no MDM2-
targeting drug has seen FDA approval78. The p53 protein, encoded by Trp53, is involved 
in critical tumor suppressor pathways and is involved in an autoregulatory loop with 
MDM2, where MDM2 negatively regulates p53 through proteasome targeted degradation 
and transcriptional regulation, and p53 target expression upregulates MDM2 (Figure I - 
4). MDM2 overexpression leading to p53 dysregulation is found in 7% of all cancers, and 
is more common in soft tissue tumors such as esophageal carcinomas79. Crystallization 
of the N-terminal region of p53 with MDM2 revealed a p53 alpha helix engaging with a 
deep groove of MDM280 with critical hydrophobic interactions mediated by F19, W23, and 
L26 of the p53 helix. Phage display has been used to find more potent inhibitors of the 
MDM2-p53 interaction than the p53 native sequence81,82 but these studies did not screen 
peptides in the context of stapling.  
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Figure I - 4. Partial map of signaling pathways involving the p53-MDM2 interaction.  
P53 functions as a tumor-suppressor gene, triggering transcription of downstream targets 
following DNA damage. MDM2 functions as a ubiquitin ligase of p53, targeting it for 
degradation, and also inhibiting p53 nuclear localization. Figure adapted from Chéne et 
al. (2003)79. 
 
The Nutlin family of small molecules, discovered by Vassilev and colleagues was 
found to bind MDM2 and block p53, activating the p53 pathway in tumor cells83. They 
were discovered through small molecule screens revealing cis-imidazoline analogs and 
exhibited 100-300 nM binding affinity values. Unfortunately, despite exciting preclinical 
and early stage clinical results, a derivative of Nutlin 3a, RG7112, exhibited poor 
pharmacokinetics and toxicity. Along with other small molecule MDM2 binders, RG7112 
also exhibited a lack of strong binding to MDMX (a related p53 suppressor), which likely 
contributed to its modest efficacy during clinical trials. The lack of engagement of Nutlin 
and Nutlin derivatives to MDMX, despite extensive structural similarities between MDM2 
and MDMX, is well documented in the literature. In one example, Hu and coworkers 
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overexpressed MDMX in a stably transfected U2OS osteosarcoma cell line and found 
lack of p53 activation in cells even when treated with Nutlin84. While MDMX does not 
participate in direct ubiquitination of p53, it forms a heterocomplex with MDM2 and is 
critical for p53 suppression in embryonic development85. Gene or protein alterations of 
MDMX are found in many cancers and the frequency is higher in tumors with wild-type 
p5385. Because of their larger surface area, alpha helical stapled peptides have shown to 
be capable of targeting both MDM2 and MDMX2. Aileron Therapeutics’ lead compound 
ALRN-6924 is currently being evaluated in phase 2 clinical trials23.  
 
Summary 
The design of stapled peptides has largely been limited to targeting interactions with a 
solved X-ray crystal structure, to which an inhibitor can be rationally designed. Even in 
this case, stabilization requires time consuming trial-and-error optimization of linker 
location (Figure I - 5) as stabilization is a major structural modification and so can also 
reduce or completely abrogate binding if the covalent bridge is made between 
inappropriate residues. Researchers routinely test multiple variants in search for optimum 
biological activity86. In one case, hydrocarbon stapling of a Bim-derived peptide exhibited 
weaker binding to Bcl-xL than the unstapled peptide87. In the complex landscape of 
protein-protein interactions, there are many such pairs in which no crystal structure exists.  
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Figure I - 5. Development of a p53 mimic for MDM2 inhibition  
Trial-and-error optimization of staple locations and amino acid sequence, adapted from 
Bernal et al. (2007)22 
 
Solid phase peptide synthesis (SPPS), today’s method of choice for producing 
peptides, has been used to generate and screen libraries of stapled molecules containing 
non-canonical amino acids88,89. The one-bead-one-compound method (OBOC) has 
significant advantages due to the vast accessible chemical space. Virtually any type of 
side chain can be incorporated by SPPS, but care must be taken to avoid generating 
peptides of different sequence but same molecular weight due to decoding accomplished 
by mass spectrometry. Because of this constraint, and also because screening for binders 
typically involves manually selecting beads in fluorescence microscopy, the library size is 
limited to about 104 members90 and thus is not tractable as a method for screening large 
libraries of stabilized peptides. Screening two residues on the outside of the stabilized 
residues and 6 residues between the stabilized residues requires a library size of about 
1010 molecules, and so OBOC screening approaches significantly undersample this 
space. Bacterial surface display enables large library sizes, to numbers not typically 
achievable by yeast, mammalian, and OBOC methods. Furthermore, the relatively facile 
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incorporation of non-canonical acids in the genetically tractable E. coli host, as well as 
ability to use quantitative FACS for sorting and analysis confers powerful advantages 
compared to phage and mRNA/ribosomal display systems. This dissertation addresses 
the need for a high throughput, combinatorial-driven method to screen large numbers of 
stabilized peptides for activity.  
 
Figure I - 6. Putting the pieces together  
We used bacterial surface display to expose libraries of peptides containing the non-
canonical amino acid azidohomoalanine. We stabilized the displayed peptides and 
screened with magnetic and fluorescent methods to discover new sequences. 
. 
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Abstract 
 
Chemically stabilized peptides have attracted intense interest by academics and 
pharmaceutical companies due to their potential to hit currently ‘undruggable’ targets. 
However, engineering an optimal sequence, stabilizing linker location, and 
physicochemical properties is a slow and arduous process. By pairing non-natural amino 
acid incorporation and cell surface click chemistry in bacteria with high-throughput sorting, 
we developed a method to quantitatively select high affinity ligands and applied the 
SPEED (Stabilized Peptide Evolution by E. coli Display) technique to develop disrupters 
of the therapeutically relevant MDM2-p53 interface. Through in situ stabilization on the 
bacterial surface, we demonstrate rapid isolation of stabilized peptides with improved 
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affinity and novel structures. Several peptides evolved a second loop including one 
sequence (Kd = 1.8 nM) containing an i, i+4 disulfide bond. NMR structural determination 
indicated a bent helix in solution and bound to MDM2. The bicyclic peptide had improved 
protease stability, and we demonstrated that protease resistance could be measured both 
on the bacterial surface and in solution, enabling the method to test and/or screen for 
additional drug-like properties critical for biologically active compounds. We show that 
surface stabilization improves the correlation between binding measured on bacterial 
surfaces and in solution, demonstrating the broad potential of this technique. 
 
Introduction 
 
Estimates based on the human genome indicate that approximately two-thirds of all 
disease-associated genes are ‘undruggable’ by current therapeutics1. They reside inside 
cells, out of the reach of biologics, but lack a small hydrophobic binding pocket necessary 
for small molecule therapeutics2,3. This has led researchers to push the limits of 
intracellular therapeutics to larger sizes, capable of binding and disrupting intracellular 
protein function. Peptides, by mimicking protein binding epitopes, are an attractive option 
for target binding, but small linear peptides typically suffer from several liabilities including 
rapid proteolysis and low binding affinity. Covalent modification of peptides, however, can 
endow these agents with drug-like properties, such as oral delivery, high affinity, and 
increased stability4–6.  
One approach to improving drug properties involves introducing a covalent linker 
between two amino acids spanning 1 or 2 turns of the helix, which can improve affinity, in 
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vivo stability, and cellular uptake7–10. A vast and diverse literature exists on chemical 
methods to modify peptides and peptide libraries to connect these residues, including 
disulfide and amide bond formation, olefin metathesis, azide-alkyne cycloaddition, aryl-
cysteine bond formation, and cysteine Michael addition, among others11–18. These 
approaches are nicely reviewed in Derda and Jafari 201819. Some of the pioneering work 
was done by Roberts and colleagues using mRNA display20 and demonstrated the power 
of stabilized libraries, and these technologies have been advanced to screen for peptides 
with multiple modifications21, bicyclic peptides17, and specific secondary structures such 
as alpha helices22.  These stabilized alpha helices in particular have multiple applications 
including molecular imaging and intracellular therapeutics to disrupt protein-protein 
interactions23. For example, the p53-MDM2 complex involves a helix on p53 interacting 
with a groove on MDM2. This therapeutically important interaction causes downregulation 
of the central tumor suppressor protein p53. Due to the high frequency of dysregulation 
in many cancer types24, there is a strong and multi-decade effort underway to develop 
better therapeutic inhibitors of this interaction. By disrupting the complex, p53 can no 
longer be downregulated by MDM2, increasing its tumor suppressor activity. Challenges 
remain for these and other stabilized peptides in this nascent field, with improvements to 
affinity, for instance, being sensitive to the positioning of the two modified amino acids 
and the linker identity. Improper peptide design can result in abrogation of binding25. 
Manual optimization of the staple position and flanking residues requires time-consuming 
solid phase peptide synthesis and affinity measurements, which results in low sampling 
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of the available design space (typically > 1012 peptide sequences) and a detrimental 
impact on peptide development. 
The inherently vast chemical and sequence spaces have led to the development 
of multiple high-throughput techniques for stabilized peptide discovery. For example, DNA 
barcoded chemical-peptide libraries with reactive cysteine bridging have been developed 
to identify molecules that bind in the sub- and low nanomolar dissociation constant (Kd) 
range. However, relatively small library sizes are typically achieved with DNA barcoded 
and one-bead-one-compound libraries. In contrast, phage display allows for much larger 
library sizes26. Phage display can suffer from difficulties in achieving the highly efficient 
non-natural amino acid incorporation that is required for certain chemistries27. The phage 
display selection process of panning also does not yield precise values of affinity or 
stability, measurements that are accessible via cell surface display techniques. Phage 
therefore requires separate solid phase peptide synthesis and affinity quantification for 
validation, similar to the staple optimization challenges described above. However, due 
to concerns over undesirable reactivity with existing ubiquitous amino acid residues (e.g. 
cysteine and lysine) involved in alkylation or amide bond forming stabilization techniques, 
these chemistries are not suitable for selective reaction on the surface of cells. Therefore, 
a bio-orthogonal stabilization chemistry (i.e. one which doesn’t react with common 
biological functional groups) was chosen for on-cell peptide stabilization and directed 
evolution. 
The demand for next-generation peptide screening approaches led us to develop 
bio-orthogonal Stabilized Peptide Evolution by E. coli Display (SPEED), an approach 
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involving display of stabilized peptides on the surface of methionine auxotrophic E. coli. 
E. coli can display a large number of peptides on the cell surface, enabling quantitative 
on-cell screening (e.g. by fluorescence activated cell sorting). Using bio-orthogonal 
chemistry, directed evolution can be performed with the stabilizing linker in place, which 
often makes important target contacts in addition to stabilizing the structure9,28. Tirrell and 
coworkers demonstrated robust and highly efficient substitution of methionine by 
azidohomoalanine (AHA) in metE knockout E. coli29, and several groups, including our 
own, have demonstrated the utility of incorporating multiple azides for cross-linking and 
helix stabilization12,13,15. By modifying the bacterial display eCPX scaffold30, we conducted 
directed evolution of a cell-surface stabilized MDM2-binding peptide library of > 108 
mutants. Using a randomization scheme that fixed the position of the cross-linking side 
chains but permitted the incorporation of natural amino acids including cysteine residues, 
we selected a novel bicyclic sequence with high affinity (1-2 orders of magnitude higher 
binding affinity than Nutlin 3a, a potent small molecular inhibitor of the intracellular p53-
MDM2 interaction) with increased protease stability. 
 
 
 
Scheme 1. Stabilized peptide engineering with E. coli display (SPEED). A: On the 
bacteria surface, the displayed peptides are reacted with a stabilizing, bis-alkyne 
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molecule (shown here as propargyl ether). B: Displaying bacteria are then incubated with 
a ligand of interest. After display, stabilization, labeling, and selection, the plasmids of 
desired cells are purified and re-transformed into fresh cells, completing the directed 
evolution cycle. 
 
 
Results 
 
In Situ Stabilization and Directed Evolution Using Chemical Biology 
Due to the complex milieu of biomolecules on the surface of bacteria compared to phage, 
we selected a bio-orthogonal chemistry for in situ conjugation and peptide stabilization 
with a linker. The use of two identical non-natural amino acids in the peptide sequence 
requires an efficient and robust system for incorporation in large libraries (due to the 
dependence on the square of the incorporation efficiency). The residue replacement 
strategy of azidohomoalanine for methionine in bacterial auxotrophs satisfies all these 
criteria as  >95% incorporation31,32 is achievable. Once displayed, the peptide was 
stabilized with a bis-alkyne linker using copper(I)-catalyzed azide-alkyne cycloaddition 
(Scheme 1A). After surface reaction, the bacteria were incubated with the target protein 
(scheme 1B) to enable selection of binders in the presence of the stabilizing cross-linker 
on a library of > 108 compounds. The cell-surface screen also allowed rapid monitoring 
of affinity maturation without the need for sequencing, peptide synthesis, and solution 
phase binding measurements33. The use of a strong promoter (T5) and removal of 
methionine residues in the eCPX protein resulted in surface expression of ~104 azide-
containing peptides per cell as quantified by fluorescent beads (Figure II - 1A) that could 
be specifically reacted (Figure II - 1B), highlighting the utility of a bio-orthogonal reaction. 
By titrating the linker concentration to balance the surface reaction yield versus doubly 
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reacted (bis-adduct) peptide (Figure II - 1C), we were able to achieve an estimated 75% 
stabilization on the surface (Figure II - 1D). The extent of stabilization was calculated 
based on measurements detailed in the methods and supporting information section 
since there is no mass change upon the 2nd cycloaddition reaction (precluding mass 
spectrometry analysis). 
 
 
Figure II - 1. Chemical Biology Enabled Stabilization.  
A: Comparison of display levels conferred by different vectors with and without 
azidohomoalanine incorporation. In this example, the 39 amino acid exendin peptide is 
displayed, labeled with an anti-exendin and fluorescent secondary antibody, and 
quantified by flow cytometry using quantitative beads (n = 3 independent bacteria 
cultures, unpaired t test two-tailed df = 4; t = 0.75, p = 0.50; t = 11.7, p = 0.0003; t = 6.61, 
p = 0.00270 respectively). B: SPD-M0-E(-2) with an HA tag generated using primers 9 
and 10 displayed and reacted with SCy5-alkyne (red) and blotted with anti-HA (blue). C: 
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Reaction progress and fraction of reacted peptides that are also stabilized as a function 
of propargyl ether concentration (n = 3 independent blots per data point). D: Fraction of 
surface displayed peptides that are stabilized as a function of propargyl ether 
concentration (n = 3 independent blots per data point). 
 
Library Design and Selection 
P53-derived peptides provided an excellent model system and medically relevant target 
to develop a cell surface display screening method for stabilized alpha helices. In the 
native p53 – MDM2 interaction, residues F19, W23, and L26 are involved in key 
hydrophobic contacts34 and mutagenesis studies have shown the importance of these for 
binding35. In fact, mutating either the phenylalanine or tryptophan to alanine (F19A or 
W23A) resulted in no detectable binding on the bacterial cell surface (Figure II - S1B). 
The individual contributions and interactions of and between other residues is less 
understood, and the formation of helix-stabilizing salt bridges and hydrogen bonding can 
influence binding10,36. In the context of chemical stabilization, we sought to investigate the 
roles of the less critical residues in native-like p53 interacting sequence 
(ETFXDLWRLLXEN) 12,37 by creating a library with NNC codons in the place of these 
amino acids while keeping the highly conserved F19, W23, L26, and azidohomoalanine 
positions 20 and 27 fixed (Figure II - 2A). The library generated had a size of 3x108 
transformants.  
One round of magnetic-activated cell sorting (MACS) and serial rounds of 
fluorescence-activated cell sorting (FACS, up to seven) on the stabilized peptide library 
were conducted to select for improved affinity to MDM2 as assessed with the bacterial 
surface-displayed stabilized peptides (Figure II - 2B,C). After each round of selection, we 
  38 
isolated the plasmids and directly transformed these into fresh cells (due to low viability 
after surface reaction) for sequencing or additional rounds of selection. Several positions 
had a high degree of residue conservation during selection, especially Y22 and D25 
(Figure II - 2B, II - S2). After round 3, the apparent binding affinity for MDM2 by stabilized 
peptides displayed on the bacteria surface was measured for several clones to verify the 
method was selecting higher affinity sequences. We measured the affinity of two clones, 
SPD-M3-G1 and SPD-M3-V1 and found apparent Kd values of 2.0 and 9.8 nM 
respectively on the bacterial cell surface, which appeared promising (Table II - I, Figure 
II - 2C). Bulk-library labeling by MDM2 showed consistent improvement in signal over 
sorts (Figures 2A, S3). We also characterized several clones from very early in the sorting 
campaign (post-MACS and post-two rounds of FACS) to demonstrate significant affinity 
improvements (Figure II - S4). After seven rounds of sorting, we found that all clones 
measured show significantly improved apparent affinity over SPD-M0-E(-2) on the 
bacterial cell surface (Figure II - S5).  
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Table II - I – Measured dissociation constants of peptides  
Kd values were determined on the bacterial surface (BSD, soluble MDM2) and in solution 
(BLI, surface-bound MDM2). Also included are CD-measured helicity values. 
 
Name Sequence BSD Kd (nM) BLI Kd (nM) Helicity (%) 
  Stabilized (S) 
Non-
stabilized 
(NS) 
Ratio 
(NS/S) 
Stabilized 
(S) 
Non-
stabilized 
(NS) 
Ratio 
(NS/S) 
 
Stabilized 
(S) 
Non-
stabilized 
(NS) 
Ratio 
(S/NS) 
SPD-
M0-E(-
2) 
 ETFXDLWRLLXEN 9.6 ± 1.6 8.7 ± 0.2 0.9 15 ± 5.3 113 ± 16 7.5 53 30 1.8 
SPD-
M0-E(-
1) 
 QTFXDLWRLLXEN 11 ± 6.2 13 ± 6.8 1.2 17 ± 3.4 157 ± 29 9.2 40 29 1.4 
SPD-
M0-E(0)  QTFXDLWRLLXQN 12 ± 4.8 17 ± 5.5 1.5 74 ± 28 
454 ± 
106 6.1 41 37 1.1 
SPD-
M3-G1 GGTFXGYWADLXAF 2.0 ± 0.31 2.9 ± 1.0 1.4 5.1 ± 3.9 21 ± 3.7 4.1 18 17 1.1 
SPD-
M3-V1 VLSFXDYWNLLXGS 9.8 ± 3.4 64 ± 33 6.6 14 ± 4.3 131 ± 40 9.4 NM NM - 
SPD-
M6-V1 VCDFXCYWNDLXGY 1.4 ± 0.10 15 ± 4.8 11 1.7 ± 0.16 6.8 ± 2.8 4 28 3 9.3 
SPD-
M0-E(-
2)-F19A 
 ETAXDLWRLLXEN ND ND ND 604 ± 177 >10,000 - 50 14 3.7 
 
 
To confirm these affinities corresponded to higher binding when the peptide is in 
solution and validate the technique, we synthesized several sequences by solid-phase 
peptide synthesis (>95% purity, Table II - S2) and measured solution phase peptide 
binding by bio-layer interferometry (BLI) with immobilized MDM2. Selected clones were 
identified for solution phase characterization and comparison with bacterial surface 
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displayed apparent binding affinity values (Table II - I). Sequences were named according 
to the convention SPD (stabilized peptide display)-M (sort round)-first amino acid and 
unique number. These included the original p53-like peptide sequence (-2 formal charge, 
SPD-M0-E(-2)) and two site-directed charge mutants (E17Q mutant with a -1 formal 
charge, SPD-M0-E(-1), and E17Q and E28Q double mutant SPD-M0-E(0)) to evaluate 
the ability to characterize charge mutants given the importance for intracellular access8,9. 
SPD-M3-G1 was chosen as a higher affinity mutant from early in the screening process 
and SPD-M3-V1 due to the large increase in apparent binding affinity upon stabilization 
on the bacterial surface. Sequencing of 40 clones from round 7 of FACS showed 
enrichment of the SPD-M6-V1 sequence (13 of 40 clones, Figure II - S5), which contained 
a pair of i, i+4 cysteine residues. Mutagenesis of either cysteine residue to serine resulted 
in a greater than two-fold loss in binding (Figure II - 2D), indicating a direct role for the 
pair and likely disulfide bond formation. While this was within our design space, the 
evolution of an i,i+4 cysteine-containing sequence was unexpected from a topological 
perspective. Mass spectrometry and NMR confirmed disulfide bond formation for the 
synthesized peptide (Tables S2 and S3). The F19A mutant of the original starting 
sequence (SPD-M0-E(-2)) was included as a negative control (SPD-M0-E(-2)-F19A). 
Development of peptide binders using bacterial surface display methods has 
sometimes led to a disconnect between the affinity of loop-insertional fusions versus 
solution phase binding38. To test the relationship between cell surface affinity 
measurements and solution phase binding, the affinity (dissociation constant) of stabilized 
and non-stabilized alpha helices was measured both on-cell (by bacterial surface display, 
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BSD) and in solution using BLI (Table II - I and Figure II - S6). We found that all 7 peptides 
for which we determined affinities exhibited improvements in binding in solution upon 
stabilization with propargyl ether, ranging from 4-fold for SPD-M6-V1 to 9.4-fold for SPD-
M3-V1 (Table II - I and Figure II - S6). The differences in apparent affinity upon 
stabilization for the bacterial surface displayed peptides were more modest. The 
stabilized peptide affinity on the bacteria surface was similar to the stabilized peptide 
affinity in solution as expected, but the non-stabilized form on-surface also had similar 
affinity as the stabilized forms for most peptides (Table II - I). Binding affinity 
measurements and selection on the bacterial cell surface were performed using 
fluorescently tagged MDM2-GST because of the spurious loss of binding for some clones 
when incubated with smaller (truncated) MDM2-fluorescent dye conjugates. These same 
clones bound biotinylated MDM2 truncate (Figure II - S4A) and fluorescent MDM2-GST 
fusion protein (Table II - I) with high affinity, indicating the dye size/charge on the smaller 
truncate was likely mediating the effect. All BLI measurements used biotinylated MDM2 
truncate. Avidity is a concern for accurate measurement of affinities on a crowded surface 
like the E. coli outer membrane. To verify the GST tag did not induce confounding effects 
from dimerization and impact affinity measurements, we measured Kd values with 
biotinylated MDM2 truncate (e.g. SPD-M6-V1 had an apparent Kd of 0.4 nM, figure S4A). 
As it did not appear that  avidity effects were playing a strong role in explaining the closer 
measured affinities of stabilized and non-stabilized peptides on the bacterial cell surface, 
we hypothesize that the secondary structure of the non-stabilized peptides may be more 
helical on the surface, potentially from molecular crowding effects from the membrane or 
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lipopolysaccharide coating39. Molecular crowding can increase peptide helicity, but even 
weak intermolecular interactions with the crowding agents can dramatically reduce the 
effect40,41, which could explain the sequence dependence of the phenomenon (Table II - 
I). Negative control peptides SPD-M0-E(-2)-F19A and SPD-M0-E(-2)-W23A did not 
exhibit measurable binding as displayed on the bacterial cell surface (Figure II - S1). 
Secondary structure (helicity) as examined by circular dichroism (CD) did not seem to 
correlate strongly with binding (Table II - I, Figure II - S7), indicating a more complex 
relationship of entropic and enthalpic effects than simply high helix pre-organization 
resulting in higher binding affinity42,43.  
 
Figure II - 2. Stabilized Peptide Library Design and Selection.  
A: top: randomization scheme for library generation showing the residues randomized 
(gray), kept constant (black), and stabilization sites (red). Bottom: population level and 
individual clone analysis by flow cytometry. Histograms are shown for approximately 
12,000 events for samples labeled with 2.5 nM MDM2-GST. “No selection” is the original 
library containing 3 x 108  transformants. “MACS” refers to the population obtained from 
one round of positive selection with magnetic beads. FACS 1, 3, 5, 7 refer to the 
populations sorted after 1, 3, 5, and 7 rounds of fluorescence-based sorting. The even-
numbered sorted populations are not shown here for clarity. B: Logo plot results of 
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selection showing relative frequencies of amino acids in non-cysteine containing 
sequences and i,i+4 containing sequences. C: SPD-M3-G1 exhibits a nearly 5-fold 
improvement in affinity over the starting sequence SPD-M0-E(-2) after only 3 rounds of 
sorting indicating the selection following surface reaction is effective (n = 3 independent 
trials of duplicates per data point, unpaired t test two-tailed,  df = 4. t = 8.036, p = 0.0013). 
D: Disulfide bond formation is important for binding of SPD-M6-V1 and mutation of one 
of the cysteine residues results in reduced affinity on the bacteria surface (n = 3 
independent trials, unpaired t test two-tailed, df = 4. t = 4.97, p = 0.0076). 
 
 
Protease stability 
For efficacy in vivo, peptides must survive protease exposure in a variety of biological 
milieus such as in the bloodstream and at the site of administration (i.e. for 
subcutaneously administered drugs7 or for oral delivery44). We assessed the stability of 
several peptides on the bacterial surface and in solution using chymotrypsin to determine 
if cell surface display would enable measurement or screening for protease stability. The 
three stabilized peptide sequences tested, SPD-M3-G1, SPD-M0-E(-2), and SPD-M6-V1 
showed the same trends on the bacterial surface (Figure II - 3A) as in solution (Figure II 
– 3B). Likewise, the non-stabilized peptides were much less protease-resistant on the 
surface (Figure II - 3C) and in solution (Figure II - 3D) as expected. Note that the time, 
temperature, and enzyme concentrations were optimized separately (surface versus 
solution) to ensure a good dynamic range for each. The disulfide loop in the SPD-M6-V1 
likely contributes to its overall higher stability properties. 
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Figure II - 3. Chymotrypsin digest trajectories.  
A: Bacteria displaying stabilized peptides were treated with chymotrypsin (1 μg/mL on 
ice) and labeled with MDM2-GST-AF647 for peptide detection. B: Stabilized peptides 
synthesized by SPPS were treated with chymotrypsin (5 μg/mL at 37 C) and quantified 
by HPLC for validation. C: As in A, except with non-stabilized peptides. D: As in B, except 
with non-stabilized peptides. 
 
Structure determination 
The directed evolution of a disulfide bond was surprising, since disulfide bonds generally 
destabilize alpha helices as seen by the low helicity signature (4%) from CD spectroscopy 
for SPD-M6-V1, non-stabilized (Table II - I and Figure II - S7). Therefore, we calculated 
the structure by solution NMR to investigate the mechanism(s) that gave this sequence a 
selective advantage. Homonuclear (1H-1H) NOESY (nuclear Overhauser effect 
spectroscopy) and TOCSY (total correlation spectroscopy) experiments were conducted 
to determine the free solution structure of the SPD-M6-V1 peptide (Figure II - 4, II - S8). 
The observed peaks implied a predominantly alpha-helical conformation for the stabilized 
structure with an interesting bend conferred by the bis-triazole linker (Figure II - 4A, Figure 
II - S7C). 1H NMR spectrum indicated no significant structural changes in the peptide 
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upon binding to MDM2, implying that the molecule is highly ordered in solution, owing to 
the stabilization conferred by both the overlapping i, i+4 disulfide bond and the i, i+7 bis-
triazole linker (Figure II - 4B,C).   
To understand the interaction of SPD-M6-V1 with MDM2, one-dimensional 
saturation transfer difference (STD) NMR experiments were performed to identify peptide 
atoms interacting with the MDM2 binding interface. These data indicate close interactions 
between the target and Val16, Cys17, and several aromatic residues. There is also an 
interaction between the bis-triazole linker and MDM2 (Figure II - 4D). This interaction 
highlights a potential enthalpic contribution from the linker in addition to the entropic 
benefit of pre-organization, another advantage of screening in the context of the linker. 
The linker-target interaction is consistent with crystallographic structures reported for 
other stabilized peptide binders of MDM228 and other proteins9.  
Computational docking using Autodock Vina software was consistent with the STD 
data. In the calculated docking poses (Figure II - 4B), the three key hydrophobic residues 
F19, W23, and L26 are oriented towards the binding pocket as expected from the 
canonical p53-MDM2 interaction. The highly conserved Y22 residue appears to lie in a 
shallow notch defined by residues 93-96 of MDM2 and may be involved in pi-CH 
interactions with K94. D17, which was observed in 100% of i,i+4 binders (Figure II - 2B) 
may play a key role in enforcing binding conformation, together with the disulfide bond.  
  46 
 
Figure II - 4. Structural characterization using solution NMR.  
A: Ensemble of 20 lowest energy structures and B: representative single structure. C: 
Docked model showing likely bound conformation. D: Saturation transfer difference (STD) 
spectrum of SPD-M6-V1 bound to MDM2.  
 
 
Discussion 
 
Small, helical peptides are under intense investigation for applications in molecular 
imaging15 and therapeutics4,10,26 due to their unique physicochemical properties and the 
possibility of hitting currently ‘undruggable’ targets. Specifically, their potential to 
overcome limitations of large biologics by entering cells and ability to target intracellular 
proteins lacking small molecule binding pockets would dramatically increase the number 
of available drug targets in the human genome. Antibody-based biologics excel at 
targeting proteins and have achieved major clinical success in oncology, immune system 
disorders, and other diseases but are limited to extracellular targets owing to their large 
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size. Small molecule drugs can readily access cytosolic targets. However, intracellular 
protein-protein interactions involve large surface areas and typically lack small 
hydrophobic binding pockets, making a small molecule approach intractable for many 
cases1,3. These physical factors can also result in low potency and off target effects by 
small molecules, as they lack the physicochemical properties to maintain high affinity and 
high selectivity. Helical peptides lie at the intersection of these two fields, where their size 
is small enough for potential cytosolic access but large enough to specifically disrupt 
protein-protein interactions prevalent in cell signaling to enable targeting of new pathways 
in disease. Intracellular delivery is still a major hurdle, and high affinity is critical to 
efficacious targeting since intracellular peptide concentrations are likely to be low.  
The complexity of protein-protein and protein-solvent interactions, particularly with 
dynamic binding interfaces, makes computational and rational design of high affinity 
binders challenging. Indeed, the design of stabilized helical peptides has largely been 
limited to targeting interactions with a solved X-ray crystal structure where an inhibitor 
can be rationally obtained45–48, prompting us to develop a directed evolution platform for 
stabilized peptide engineering of novel drug leads on the cell surface, with several 
advantages over current techniques. 
As ‘guardian of the genome,’ the critical p53 tumor suppressor protein is often 
disrupted in cancer, including through downregulation by the ubiquitin ligase MDM224. 
Recent peptide efforts toward targeting the p53-MDM2 interaction have centered around 
hydrocarbon stapling, a promising approach with one candidate ALRN-6924 currently in 
phase II clinical trials5. Stapling is thought to confer improvements in binding from locking 
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one or more turns of a peptide, resulting in helical preorganization. However, current 
technologies for engineering these structures have several drawbacks including limited 
library size, multi-step characterization, or sequential sequence/linker optimization that 
can miss synergistic interactions. Given the importance of the therapeutic target and 
knowledge base around this protein interface10,34,35, we used the p53-like peptide as a 
model system for engineering high affinity alpha helices using in situ stabilization. 
In this approach, we applied non-natural amino acid incorporation and bio-
orthogonal chemistry for in situ stabilization of surface displayed peptides followed by 
directed evolution using E. coli to engineer high affinity molecules (Scheme 1). Bacterial 
display allows rapid identification and decoding of high affinity binders through surface-
enabled affinity measurements (in contrast to phage display, mRNA display, and bead-
based libraries) and high throughput screening, enabled by larger libraries than typically 
generated with peptide arrays, one-bead-one-compound, yeast surface and mammalian 
surface display. Furthermore, we could characterize binding of several thousand clones 
by flow cytometry after every round of sorting (Figure II - 2A), allowing us to monitor 
selection progress in a straightforward manner. Engineering the display and stabilization 
reaction on the surface of bacteria using chemical biology techniques (Figure I - ) resulted 
in the selection of high affinity sequences (low single-digit nanomolar dissociation 
constants) with improved binding affinity in the stabilized form (Figure II - 2).  
Binding of multivalent ligands to the cell surface can result in avidity effects where, 
for example, rebinding of the second domain in a bivalent interaction slows apparent 
dissociation. Because GST fusion can cause dimerization of the binding domain49(MDM2 
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in this example), we designed the selection scheme to mitigate potential impacts of avidity 
and expression levels on the cell surface. For several sorting rounds, we ran a competition 
sort where we first labeled with AF647-MDM2-GST followed by a wash and AF488-
MDM2-GST. The addition of the competitor AF488-tagged molecule in excess would be 
able to effectively compete off AF647-MDM2-GST with high avidity/low affinity by 
preventing rebinding but not impact high affinity interactions that lack fast dissociation 
and rebinding. Because these rounds selected for high AF647 relative to AF488, only 
those clones with high monovalent affinity that were resistant to competition by AF488-
MDM2-GST would be selected. This is seen with the lead clone selected from the sort 
(SPD-M6-V1) having a high monovalent affinity with similar measurements by BLI and on 
the bacterial surface. However, avidity could be leveraged with this technique to improve 
the selection of very weak binders early in the directed evolution process, such as by 
preloading magnetic beads with biotinylated target to increase multivalent interactions. 
One of the original goals of screening peptides containing a cross-linking ‘staple’, 
as opposed to post-screening stapling, was to avoid steric clashes that would result in 
‘false positives’ during the selection process (i.e. sequences selected from the library that 
lose affinity after the addition of the linker). This is indeed the case, where placing the 
linker in a different location lowers the affinity on the bacterial surface (data not shown). 
We were also able to generate a series of affinity mutants with varying charge and 
lipophilicity for future investigation, given the importance of physicochemical properties 
on cytosolic access8,9 and the potential to detect favorable interactions with the staple 
itself9,28. Interestingly, there were some sequences (e.g. SPD-M3-V1) that had a low 
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apparent binding affinity when not stabilized on the bacterial surface (Kd = 64 nM) but 
demonstrated high apparent affinity when stabilized on the bacterial surface (Kd = 9.8 nM) 
or in solution (Kd = 14 nM). This indicates that stabilization can also help avoid ‘false 
negatives’ where a sequence that exhibits high affinity when stabilized in solution (a 
desired sequence) might be missed when using a selection scheme without surface 
stabilization due to low apparent affinity (when non-stabilized) on the bacterial surface. 
From a structural perspective, our work here suggests that stabilization of a single 
helix improves selection of high affinity ligands, but using directed evolution, we found an 
additional conformational constraint that further enhanced binding to the target: disulfide 
loops (Figures 3B and 3D). We did not anticipate the selection of disulfide bonds since 
they typically destabilize alpha helices and the peptides bind MDM2 in a helical 
conformation. However, we did allow for selection of peptides containing cysteines 
through the NNC degenerate codon, so disulfide bonds were within the possible evolution 
space. In fact, over two-thirds of the clones sequenced after round 7 of FACS had 
cysteines at i,i+4 or i,i+5 positions, strongly suggesting selection pressure for disulfide 
bonds (Figure II - S5A). While increased constraint within a binding partner does not 
necessarily result in improved affinity due to enthalpy/entropy compensation43, disulfide 
bonds often evolve under selection to improve the binding energy of proteins/peptides50. 
We obtained 3D NMR structures to get a more detailed picture of the impact of pre-
organization on binding. NMR data and docking analysis showed interactions between 
the cysteine residues and MDM2, one interaction between the linker structure and MDM2, 
and a rigid structure induced by both constraints (Figure II - 4C and 4D). Therefore, the 
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affinity improvements observed upon linker stabilization appear to result from both 
entropic contributions (conformational constraint) and direct enthalpic interactions. This 
is similar to the interactions observed between other stapled peptides and their targets, 
including an MCL-1 binding molecule9 and a p53-based hydrocarbon stapled peptide and 
MDM26, and it supports the strategy of directed evolution in the presence of the linker as 
demonstrated here. We hypothesize that the disulfide bond further constrains the 
structure in parallel with the bis-triazole staple. Together, we posit that this structural 
rigidity confers binding improvements through a decrease in entropic penalty of binding 
and direct interactions further contribute to the free energy of binding.  
Notably, the highest affinity sequence from the selection, the disulfide-containing 
peptide SPD-M6-V1, would likely not have been discovered using non-orthogonal 
cysteine-directed strategies such as alkylation28 or arylation17. SPD-M6-V1 without 
stabilization exhibits poor helicity (Table II - I), which is partially remedied by reaction with 
the bis-alkyne linker, and this results in high affinity. Its relatively poor bacterial surface 
affinity without click stabilization (15 nM, worse than the original template sequence) also 
implies that stabilization prior to sorting was necessary for discovery. The original linear 
starting sequence (Kd = 113 nM, table II - 1) had an affinity similar to the MDM2 inhibitor 
Nutlin 3a11. Click-stabilization increased the affinity ~7-fold followed by directed evolution 
to improve the affinity ~8-fold yielding a 1.8 nM binder. This value is similar to the reported 
Kd of pDI (8 nM for sequence LTFEHYWAQLTS51). However, pDI is a linear peptide with 
negligible activity in cells52, likely due to proteolytic instability and reduced intramolecular 
hydrogen bonding for crossing membranes. Therefore, it required extensive stapling and 
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amino acid optimization to develop ATSP-704151, the preclinical precursor to ALRN-6924. 
The current platform yielded a high affinity stabilized peptide binder directly from the 
library and work is ongoing to investigate sequence- and linker- dependence on cellular 
and in vivo efficacy.  
We were surprised to find that the correlation between the binding affinity on the 
bacterial surface and in solution was stronger for the stabilized peptides than the linear 
versions (Table II - I and Figure II - S11). In particular, the higher apparent affinity of 
unstabilized peptides on the bacterial cell surface relative to affinities in solution was 
unexpected. These peptides are fused only by their C-termini, so they are not within a 
constrained loop. The outer leaflet in gram negative bacteria such as E. coli is primarily 
composed of lipopolysaccharide (LPS) that forms a coat that is several nanometers in 
thickness39. We speculate that the observed enhancement of surface affinity without 
chemical stabilization could be due to increased helicity/pre-organization from molecular 
crowding on the bacterial surface. Molecular crowding can increase peptide helicity, but 
even weak intermolecular interactions with the crowding agents can dramatically reduce 
the effect40,41, which could explain the sequence dependence of the phenomenon (Table 
II - I). We speculate that the bacterial surface environment itself may have imparted some 
helicity resulting in affinities closer to the stabilized alpha helices but in a less robust 
manner than stabilization by the linker. 
Despite the advantages of this approach, there are several limitations and areas 
for improvement. Even with library sizes of ~109 in bacteria, the diversity of 11 positions 
is still much larger at ~2x1014. Computational methods (eg. by Bullock 20116) could be 
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used as a starting point followed by maturation of affinity, linker location, and stability 
using the present approach. For three key properties of intracellular biologics – 
membrane permeability, binding affinity, and stability – only the latter two can be 
engineered with the presented approach. As knowledge around membrane permeability 
improves, deep sequencing of libraries53 sorted for affinity and stability could be used to 
identify peptides with properties associated with improved membrane permeability, such 
as high amphiphilic moments. Finally, the proximity of helices to the bacterial surface 
could impact quantitative measurements. As non-natural amino acid incorporation 
improves in other organisms such as yeast54, where the Aga2 mating protein involved in 
extracellular protein-protein interactions (flocculation) has been adapted for surface 
display and panning33, additional cell-surface methods may improve the molecular 
engineering of stabilized alpha helices. 
This work represents a unique application of helix stabilization and cell surface 
display to engineer new affinity ligands. The directed evolution of stabilized helices 
yielded the novel bicyclic peptide SPD-M6-V1 containing a disulfide bond and double-
click staple for the two macrocycles, a motif that due to its high binding affinity and 
customizability has translational potential upon chemical optimization (such as replacing 
the disulfide with an intracellularly stable linker). The stability and intra-molecular 
hydrogen bonding from these stabilized alpha helices increase the efficiency of 
intracellular delivery55 and are the subject of current investigation in our lab and others. 
The surface display and binding of other peptides (Figure II - S9) highlights the potential 
for using this technique against additional targets. In summary, the combination of non-
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natural amino acid incorporation and bio-orthogonal chemistry can be used with directed 
evolution for the molecular engineering of high affinity stabilized alpha helices through in 
situ stabilization and screening for novel drug leads. 
 
Methods 
 
Plasmid construction and library design 
All primers were purchased from Integrated DNA Technologies (Coralville, IA), and all 
restriction enzymes were purchased from New England Biolabs (Ipswich, MA). The eCPX 
gene from pB33eCPX (a gift from P.S Daugherty, Addgene plasmid # 23336) was 
modified to avoid extraneous AHA incorporation and reaction. All non-start codon 
methionine sites (M99, M153, M156) were mutated56 to leucine with primers 1 and 2 to 
generate pB33-eCPX(-met) without a significant difference in surface display levels. 
eCPX(-met) was inserted into pqe80L using EcoRI and HindIII sites with primers 3 and 4 
(see Table II - S1).  
For surface display comparisons of vector systems, exendin-4 was cloned into 
pB33eCPX using primers 5 and 2 with SfiI as described in ref. 57. Exendin-4 was cloned 
into pet28A using primers 6 and 2 with pB33eCPX(-met)-exendin as the template, and 
restriction enzymes NcoI and HindIII.  
The p53-like-peptide sequence ETFMDLWRLLMEN (SPD-M0-E(-2)) was cloned 
into pqe80L-eCPX(-met) using primers 7 and 8 to generate pQE80L-eCPX(-met)-SPD-
M0-E(-2). For surface chemistry optimization, the HA tag was cloned adjacent and 
downstream of the peptide using SOE PCR with primers 9, 10, 8, and 11.  
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A library containing NNC degenerate codons to mutate all positions in the SPD-
M0-E(-2) sequence except F19, M20, W23, L26, and M27 was generated using PCR as 
detailed in ref. 57 using primers 12 and 8 using pQE80L-eCPX(-met) as the template.  
Charge mutants involving the mutations E17Q and E28Q were made using primers 13 
and 14 using pQE80L-eCPX(-met)-SPD-M0-E(-2) as the template to generate SPD-M0-
E(-1) and SPD-M0-E(0). 
SfiI cut and gel extracted insert was ligated into SfiI cut pQE80L-eCPX(-met) and 
transformed into electrocompetent methionine auxotrophic E. coli, a generous gift from J. 
van Deventer with cloning procedures adapted from ref. 57. 
 
Surface display of individual clones 
Individual clones were grown overnight at 37°C in M9 medium containing 20 amino acids 
as described in ref. 58 and diluted 1:25 in M9 + 20 AAs. Cells were grown to OD600 0.6-1 
(about 3 hours) at 37°C, centrifuged at 4000xg for 5 minutes, and then grown for 30 
minutes in M9 medium containing 19 amino acids (no methionine) for metabolic depletion. 
Cells were centrifuged and then induced with 0.5 mM IPTG in M9 medium with 19 amino 
acids and 40 μg/mL azidohomoalanine at room temperature for 3 hours. 
Azidohomoalanine was synthesized in-house according to ref. 59. Cells were then 
reacted as below. 
For flow cytometric quantification of exendin display in various vector systems, 
cells with the respective plasmid were induced as above and labeled with 10 μg/mL 
mouse anti-exendin (Abcam ab23407) in PBS/0.2% BSA. Cells were pelleted and 
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resuspended in PBS/BSA containing 10 μg/mL chicken anti-mouse AF647 (Thermo 
Fisher) and analyzed by flow cytometry. Median fluorescent values were compared with 
a standard curve made from Quantum Simply Cellular anti-Mouse beads (Bangs 
Laboratories) labelled with the same stock of chicken anti-mouse AF647.   
 
Display and reaction conditions 
The pBAD33 arabinose promoter system (originally utilized for bacterial surface display 
for tightly controllable expression and low induction-driven toxicity60) resulted in poor 
expression of peptide displayed in AHA incorporation conditions (Figure I - A). Likewise, 
low levels of display were obtained with the pET28A T7 system commonly used for over-
induction of recombinant proteins, as was similarly observed by Ayyadurai and coworkers 
with homopropargylglycine (HPG)61. Cloning of the gene into the pQE80L/T5 vector 
(Figure II - S10C) resulted in robust expression under both methionine and AHA 
incorporation conditions, and reaction and gel analysis showed promising specificity of 
AHA incorporation (Figure II - 1B). Mutation of all non-start codon methionine sites (M99, 
M153, M156) resulted in decreased extraneous reaction (Figure II - S10A). 
We optimized reaction conditions to maximize stabilized peptide yield on-surface. 
Propargyl ether was chosen as the bis-alkyne linker to connect the i, i+7 azides in the 
peptide sequences due to its helix-inducing propensity15, flexibility, and solubility. With 
directed evolution using cell surface display, typically selected cells are immediately 
cultured after sorting, but the copper catalyst needed for the azide-alkyne stabilization 
reaction is toxic to bacteria62. We therefore tested several copper chelators (based on 
previously reported improvements in toxicity and reactivity63) and temperature/time 
  57 
conditions but found that in order to achieve high reaction efficiency, the viability of the 
bacteria was too low for continual outgrowth after sorting (data not shown).  The plasmids 
could be ‘rescued’ from the sorted bacteria by polymerase chain reaction (PCR), but PCR 
can introduce errors and biases into the sorted libraries (especially when the diversity is 
high)64. To avoid this bias, we directly transformed the plasmids into new bacteria 
following whole plasmid extraction with good yield65. The transformation efficiency of this 
step was approximately 1/3 of the number of sorted cells, in line with ref. 65, so we 
oversampled our desired stringency typically by 20x to account for sequence coverage 
and loss of clones from transformation. For example, with a library of diversity 1x106 
clones where the brightest 1% of cells were desired, 2x107 cells were sampled and 2x105 
cells were collected, which typically yielded 6x104 transformants. 
We performed quantitative fluorescence analysis on western blots of cells reacted 
with either SulfoCy5-alkyne or SulfoCy5.5-azide dyes after reaction with the linker and 
normalized the signal to an anti-hemagglutinin tag (Figure II - 1C). From these 
experiments, we deduced the fraction of displayed peptide-specific azides that were 
reacted and the fraction of reacted peptides that were also stabilized to calculate the 
overall stabilization efficiency (Figure II - 1D) by fitting to a series of reaction equations 
(supporting information) since mass spectrometry cannot track the 2nd intramolecular 
stabilizing reaction. The concentration of propargyl ether that gave the best stabilization 
was 500 μM; this was used for all selection and characterization experiments. 
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Library expression 
The libraries encoding p53 peptide variants were grown from frozen stock in M9 medium 
containing all 20 amino acids at 5-10x sequence coverage at starting OD600 of 
approximately 0.1. At OD600 0.6-1, cells were centrifuged at 4000xg and methionine 
depleted for 30 minutes in M9 medium containing 19 amino acids (without methionine). 
Cells were centrifuged and then induced with 0.5 mM IPTG at room temperature in M9 
medium containing 19 amino acids and 40 μg/mL azidohomoalanine for 4 hours at room 
temperature. Cells were then reacted as below. 
 
On surface reaction of displayed peptide 
For reaction characterization and binding measurements of unique sequences, typically 
1 mL induced cells displaying AHA-incorporated peptide were centrifuged at 4000xg for 
2 min and washed twice with ice-cold PBS (155 mM NaCl, 1 mM potassium phosphate, 
3 mM sodium phosphate pH 7.4). The pellet was then reacted in 1.8 mL ice-cold PBS 
containing 100 μM CuSO4, 500 μM Tris(3-hydroxypropyltriazolylmethyl)amine (THPTA), 
5 mM sodium ascorbate, and 500 μM propargyl ether for 4 h at 4°C. After the reaction, 
the cells were pelleted and resuspended in 1 mL PBS containing 0.2% w/v bovine serum 
albumin (PBS/BSA). For library selections, these volumes were scaled up accordingly.  
For surface reaction optimization, cells displaying AHA-incorporated SPD-M0-E(-
2)-HA were washed once in PBS following propargyl ether reaction and then reacted 
further with 50 μM SCy5-alkyne or SCy5.5-azide with 100 μM CuSO4, 500 μM THPTA, 
and 5 mM sodium ascorbate overnight. Cells were then pelleted, washed 1X with cold 
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PBS, and then resuspended in 1 mL PBS. For each well, 5 μL cells were lysed in a total 
volume of 20 μL containing 50 mM Tris-HCl pH 6.8, 2% SDS, 10% glycerol, 1% beta-
mercaptoethanol and 12.5 mM EDTA, and loaded onto a Bolt 4-12% Bis-Tris Plus gel 
(Invitrogen). Bands were transferred to a PVDF membrane using the iBlot system 
(Thermo Fisher), blocked overnight at 4°C with gentle shaking with 2% BSA in Tris-
buffered saline with 0.1% Tween 20 (TBST), and probed with 2 μg/mL anti-HA in TBST 
(Thermo Fisher, clone 2-2.2.14) with 0.2% BSA for 4 hours at room temperature. After 3 
washes in TBST, the membrane was probed with 1 μg/mL goat anti-mouse-IRDye800CW 
(Licor) for 1 hour at room temperature. The blot was scanned on a Licor Odyssey CLx 
scanning fluorescence imager following 3 washes in TBST and bands quantitated. The 
ratio of 700 nm channel fluorescence (for SCy5 and SCy5.5 dyes) to 800 nm channel (for 
anti-HA, loading normalization) was reported.  
 
Protein expression and purification 
pGEX-4T MDM2 WT was a gift from Mien-Chie Hung (Addgene plasmid # 16237) and 
was transformed into BL21DE3 cells and induced by 0.5 mM IPTG at 30°C for 5 hours 
after reaching OD600 = 1.0. Expressed GST-tagged MDM2 was purified as described by 
ref 66. 
 
Magnetic selection with MDM2 
MDM2-GST was biotinylated by reaction with NHS-PEG4-Biotin (Thermo Fisher). Library-
expressing and reacted cells were labelled with 2 nM biotin-MDM2 at 4°C for 1 hour in 15 
mL PBS/BSA and cells were washed once with PBS/BSA to remove weakly-bound and 
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residual biotin-MDM2. Labelled cells were incubated with Dynabeads MyOne Streptavidin 
T1 (Thermo Fisher) in a 1:1 ratio with end-over-end rotation at 30 rpm using MACSmix 
(Miltenyi Biotec). Following incubation, magnetic beads were isolated by application of a 
magnetic field and beads washed twice with 15 mL PBS/BSA. DNA from bound cells was 
isolated as follows: beads were resuspended in 250 μL buffer P1 from the Qiaprep spin 
miniprep kit (Qiagen), bound cells lysed with 250 μL buffer P2, and neutralized with 350 
μL buffer. After centrifugation, the supernatant was applied to a Qiaprep column and after 
washing with buffer PE, DNA was eluted with 30 μL H2O (yielding approximately 100 ng 
DNA) and re-transformed into electrocompetent methionine auxotrophic E. coli.  
 
Fluorescence activated selection with MDM2 
Following library expression and surface stabilization, the MACS sorted library underwent 
selection by increasingly stringent rounds of FACS on a MoFlo Astrios instrument as 
follows: FACS round 1: labeled with 1.5 nM MDM2-AF647, brightest 1.2% of events 
collected, 3x105 transformants obtained; round 2: labeled with 0.2 nM MDM2-AF647, 
brightest 1.2% of events collected, 1.1x105 transformants obtained; round 3: labeled with 
20 nM MDM2-AF647 for 30 min, washed 2x, labeled with MDM2-AF488 at 200 nM. Top 
2.5% of events positive for AF647 and low for AF488 collected, 1.1x105 transformants 
obtained; round 4: similar scheme as round 3, brightest 15% of cells collected, 2.3x105 
transformants obtained; round 5: similar scheme as round 3, brightest 2% of events 
collected, 1.8x105 transformants obtained; round 6: labeled with 0.5 nM MDM2-AF647, 
brightest 1% of events collected, 3.0 x104 transformants obtained; round 7: labeled with 
0.5 nM MDM2-AF647, brightest 0.05% of events collected, 3.2x103 transformants 
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obtained. All cell labeling steps with primary MDM2-AF647 were done for a minimum of 
four hours prior to sorting, and all labeling steps with secondary MDM2-AF488 were done 
for a minimum of one hour. 
The plasmid contents of selected cells were extracted as detailed in ref. 65 and re-
transformed into electrocompetent methionine auxotrophic E. coli for further selection 
and/or binding characterization. 
 
Characterization of selected clones 
From each round of selection, typically 8 clones were sequenced by Sanger sequencing 
(32 clones were sequenced after FACS round 7) using primer 11.  For characterization 
of individual clones, each clone was grown up and reacted as detailed previously. For 
binding titrations, appropriate concentrations and volumes (10-fold excess) of 
AlexaFluor647 tagged MDM2-GST diluted with PBS with 0.2% BSA was added to 
approximately 1x106 cells and incubated on ice for 3 hours. Labeled cells were 
centrifuged at 4000xg for 2 minutes, washed once with 300 μL PBS with 0.2% BSA, and 
resuspended in 200 μL PBS for analysis by flow cytometry (Attune Focusing Cytometer). 
Median fluorescence intensities were normalized to the highest concentration and fit to a 
one-site binding model in GraphPad Prism v. 6.  
 
Peptide Synthesis and Stabilization 
Solid phase peptide synthesis of i,i+7 diazido peptides was carried out using a CEM 
Liberty Blue Microwave Peptide Synthesizer with 0.3 mmol/g loading Rink amide resin 
and Fmoc amino acids in dimethylformamide (DMF). The peptides were synthesized at 
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0.05 mmol scale and cleaved by addition of a cocktail composed of 93% (v/v) 
trifluoroacetic acid (TFA), 5% (v/v) H2O, 5% (w/v) phenol, and 2% (v/v) triisopropylsilane 
(TIPS). The resulting solution was evaporated under nitrogen to a small volume and 
precipitated via dropwise addition to tert-butyl methyl ether. The precipitate was then 
collected, lyophilized, and purified by preparative reverse phase gradient HPLC with 
water and acetonitrile mobile phases buffered with 0.1% TFA for all peptides except for 
SPD-M6-V1, which was purified with 25 mM triethylammonium acetate (TEAA) in 
H2O/MeCN. The resin and Fmoc amino acids were purchased from ChemPep Inc. Fmoc-
Azidohomoalanine was synthesized as in the method outlined by Lau67 or purchased from 
ChemPep, Inc. All other reagents were purchased from Sigma Aldrich. 
Diazido peptides were stabilized in solution via copper catalyzed azide alkyne 
cycloaddition. Peptides were stabilized in 1:1 water:tert-butanol at 1 mM concentration (1 
equiv) with propargyl ether (1 equiv) by addition of copper (II) sulfate (10 equiv), tris(3-
hydroxypropyltriazolylmethyl)amine (10 equiv) and sodium ascorbate (50 equiv) at room 
temperature overnight. The reaction mixtures were purified by HPLC in water and 
acetonitrile mobile phases buffered with 0.1% TFA (except for SPD-M6-V1 which was 
purified in triethylammonium acetate (25 mM) in H2O/MeCN) and the product fractions 
were lyophilized and characterized via electrospray ionization mass spectrometry (ESI-
MS) and reported in Table II - S2. 
 
Solution phase binding kinetics 
Binding affinities with the peptide in solution were measured via biolayer interferometry 
(BLI) using an Octet RED96 system (Pall ForteBio). MDM2 truncate (residues 10-118, 
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provided by Prof. Jeanne Stuckey) was biotinylated with NHS-PEG4-Biotin (Thermo 
Fisher). The resulting protein was diluted to 500 nM in the assay buffer (0.3% (w/v) bovine 
serum albumin (BSA) in phosphate buffered saline (PBS)) and loaded onto Super 
Streptavidin Biosensors. Peptide samples were prepared in the same assay buffer and 
each measurement was done in a 96 well plate using 10 concentrations per peptide. 
Resulting binding curves were fitted using Graphpad Prism v. 6. For each peptide, 
dissociation data was globally fit for all concentrations using a one-phase exponential 
decay model to yield koff. The association data were fit for each concentration to yield 
values for kon, and Kd is reported as koff / kon. The reported standard deviations of  Kd are 
between values from all data sets (~8 association/dissociation curves per peptide each 
day measured on 3 separate days).  
 
Circular Dichroism 
Solution phase peptide helicity values were estimated by circular dichroism on a JASCO 
J-815 spectropolarimeter. Samples were diluted in 1:1 water:acetonitrile to 10 μM and 
transferred to a 1 mm path length quartz cell. Measurements were recorded in three 
accumulations from 250 nm to 190 nm. Percent helicity values were determined from 
molar ellipticity at 222 nm divided by the calculated maximum molar ellipticity for 13 and 
14-mer peptides.  
 
NMR Spectroscopy, Data Processing, and Structure Calculations  
High-resolution NMR spectra of free SPD-M6-V1 peptide were obtained in sodium 
phosphate buffer, pH 6.8. Lyophilized peptide (SPD-M6-V1) was dissolved in 10 mM 
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aqueous sodium phosphate buffer (pH 6.8) with 10% D2O to a final concentration of 300 
μM. All NMR spectral measurements were acquired at room temperature (298K) in a 
Bruker AVANCE II 600 MHz spectrometer equipped with a cryoprobe and water signal 
was suppressed using WATERGATE. For resonance assignment and NOE contacts, 2-
D homonuclear TOCSY (mixing time 80 ms with 32 scans) & NOESY (mixing time 200 
ms with 88 scans) experiments were acquired using spectral width of 13 ppm with 2 K × 
512 complex points and the States-TPPI for quadrature detection at the t1 dimension. To 
probe the interactions of SPD-M6-V1 with MDM2, a saturation transfer difference (STD) 
experiment was conducted by addition of MDM2(10-118) to a final concentration of 9 μM, 
pH 6.8. MDM2(10-118) was saturated at 0.15 ppm with a cascade of 40 selective 
Gaussian-shaped pulses (49 ms each) in an interval of 1 ms resulting in total saturation 
time of 2 s. An identical experiment one-dimensional STD experiment (as a control) was 
conducted with only SPD-M6-V1 peptide at same concentration. All NMR data were 
processed using TopSpin 2.6 (Bruker), and the chemical shifts were referenced directly 
to the frequency of water (4.7 ppm). After zero filling along the t1 dimension, 2 K (t2) × 1 
K (t1) data matrices were obtained. All the spin system assignment and spectral analysis 
were done using SPARKY 3.11368. 
Sequence-specific resonance assignments of peptide was achieved by analyses 
of two-dimensional 1H–1H TOCSY and NOESY spectra69. Most of the resonances of SPD-
M6-V1 are unambiguously identified (Figure II - S8). Analyses of 1H–1H NOESY spectra 
reveal backbone/backbone, backbone/sidechain, and sidechain/sidechain NOE contacts 
for the peptide. SVD-M6-V1 peptide contains 4 aromatic amino acids and a number of 
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NOEs could be identified involving aromatic ring protons with the backbone and side 
chain protons of aliphatic residues (Figure II - S8C). NOE contacts detected for peptide 
folding are summarized in Figure II - S8B and characterized by sequential and medium 
range interactions. 
Assigned NOESY peaks were classified as weak, medium or strong and translated 
to an upper bound distance restraints: 5.0, 3.5 and 2.8 Ǻ, respectively. Backbone dihedral 
angles φ and ψ were predicted using TALOS using 1Hα chemical shifts. The structure of 
SPD-M6-V1 was calculated using CYANA 2.1. The CYANA library for the unnatural amino 
acid was created using the algorithm cylib developed by the Güntert group70 (Table II - 
S5). During the CYANA runs, both amino acids (X20 and X27) were combined through 
an oxo group (Figure II - 4A) in side chains of the unnatural amino acids. The structure 
calculation was done in a stepwise manner to get the final ensemble with low RMSD and 
low violation of distance and dihedral angle constraints. 
 
Protease digests 
On-surface peptides were expressed as mentioned above and approximately 105 
displaying bacteria were incubated with 1 μg/mL chymotrypsin in 80 μL PBS on ice. At 
each time point, samples were quenched by addition to 2% BSA in PBS, centrifuged and 
resuspended in 0.2% BSA in PBS. Resulting cells were labelled with 50 nM MDM2-GST-
AF647 on ice for 2 h in 0.2% PBS/BSA, washed, and analyzed by flow cytometry (Biorad 
ZE5). Median fluorescent intensities were analyzed to obtain the curves in Figures II - 3A 
and II - 3C. For in solution measurements of protease degradation, stabilized and non-
stabilized peptides were incubated with chymotrypsin at 5 μg/mL in PBS. Peptides were 
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first diluted to 50 μM in PBS before adding the enzyme and incubating at 37 C. After each 
time point, samples were flash-frozen in liquid nitrogen to stop digestion and stored at -
80 C until analysis. Samples were analyzed via reverse-phase HPLC at 214 nm and 280 
nm wavelengths. The fraction of intact peptide remaining at each time point was 
quantified by the AUC of the intact peptide peak on the chromatograph at 214 nm. 
Exponential decay curves and half-lives were fit in GraphPad Prism v.8. 
 
Structure-guided docking 
AutoDock Vina71 was used to dock the calculated solution structure of SPD-M6-V1 to the 
MDM2 crystal structures in 3EQS51.  Alignment of several crystal structures (2GV2, 1T4F, 
1YRC, 3V3B, 4HFZ, 3G03, 3EQS) MDM2 showed similar binding groove composition 
and amino acid side chain conformation, so 3EQS was selected for structure-based 
docking. MDM2 and peptide were pH-adjusted to physiological pH (7.4) using the 
PDB2PQR server72. AutoDockTools (ADT) was used to prepare the protein and peptide 
PDB files and determine the search space for conformational flexibility. MDM2 residue 
side chains on the periphery of the binding pocket (L54, F55, Y100) were allowed to flex 
using ADT. Polar hydrogen atoms were added, non-polar ones were removed, and 
Gasteiger partial atom charges were calculated. Structures were visualized using PyMOL 
(Schrödinger, Delano Scientific, LLC, New York, NY, USA). The selected structure 
(Figure II - 4B) was chosen based on agreement with experimental data (Figure II - 4C) 
showing interactions between MDM2 and V16, C18, F19, Y22, and W23. 
 
Statistics 
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Statistical analyses for Figs. 1A, 2C, and 2D were performed in GraphPad Prism v. 6. 
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Supporting information 
Table II - S1 – Primers used 
 
No. Description Sequence 
1 Met removal 1 CAACCCGCTGGAAAACGTTGCTCTGGACTTCTCTTACG 
2 Met removal 2 ACGCTCAGGGCCAACTGAACAAACTGGGCGGTTTCAACCTGAAATACCGCT 
3 
EcoRI eCPX for 
pQE80L 
insertion 
CACAGAATTCATTAAAGAGGAGAAATTAACTATGAAAAAAATT
GCATGTCTTTCAGCACT 
4 pB33 rev GGCTGAAAATCTTCTCTC 
5 eCPX-exendin fwd 
ACTTCCGTAGCTGGCCAGTCTGGCCAGCATGGCGAAGGCA
CCTTTACCAGCGATCTGAGCAAACAGATGGAAGAAGAAGCG
GTGCGTATGTTTATTGAATGGCTGAAAAACGGTGGTCCAAG
CAGCGGTGCACCACCACCAAGCGGAGGGCAGTCTGGGCAG
TCTG 
6 NcoI-eCPX GAATTCGAGCTCGCCATGGGTACCTTTGAGGTGGTTATG 
7 PLP-eCPX 
ACTTCCGTAGCTGGCCAGTCTGGCCAGGAAACCTTTATGGA
TCTGTGGCGCCTGCTGATGGAAAACGGCGGTGGCAGCGGA
GGGCAGTCTGGGCAGTCTG 
8 pQE80L rev GAGGTCATTACTGGATCTATCAACAGGAGTCCAAGCTCAGC 
9 PLP-HA fwd TATCCGTACGATGTGCCGGATTATGCGGGAGGGCAGTCTGGGCAGTCT 
10 PLP-HA rev CGCATAATCCGGCACATCGTACGGATAGCTGCCACCGCCGTTTTCCAT 
11 pQE80L fwd CCCGAAAAGTGCCACCTGACG 
12 NNC PLP 
ACTTCCGTAGCTGGCCAGTCTGGCCAGNNCNNCNNCTTTAT
GNNCNNCTGGNNCNNCCTGATGNNCNNCGGCGGTGGCAGC
GGAGGGCAGTCTGGGCAGTCTG 
13 E17Q for PLP(-1) 
TCCGTAGCTGGCCAGTCTGGCCAGCAAACCTTTATGGATCT
GTGGCGCCTGC 
14 E28Q for PLP(0) ACCTTTATGGATCTGTGGCGCCTGCTGATGCAAAACGGCGGTGGCAGCGGAGGGCAGT 
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Table II - S2 – Peptide mass spectrometry and purity 
 
Name Sequence Stabilized % Purity Non-stabilized % Purity 
  Predicted Mass 
Observed 
Mass 
HPLC 
at 214 
nm 
Predicted 
Mass 
Observed 
Mass 
HPLC at 
214 nm 
SPD-M0-E(-2)  ETFXDLWRLLXEN 1823.0 1823.0 97.7% 1728.9 1728.9 >98% 
SPD-M0-E(-1)  QTFXDLWRLLXEN 1822.0 1822.0 95.8% 1727.9 1727.9 95.4% 
SPD-M0-E(0)  QTFXDLWRLLXQN 1821.0 1821.0 95.1% 1726.9 1726.9 97.7% 
SPD-M3-G1  GGTFXGYWADLXAF 1690.3 1690.8 96.2% 1596.7 1596.7 >98% 
SPD-M3-V1  VLSFXDYWNLLXGS 1800.9 1800.9 >98% 1705.8 1706.8 >98% 
SPD-M6-V1  VCDFXCYWNDLXGY 1881.7 1881.0 >98% 1787.7 1787.7 97.5% 
SPD-M0-E(-
2)-F19A  ETAXDLWRLLXEN 1746.9 1746.9 >95% 1652.8 1652.8 >95% 
 
  70 
 
Table II - S3 – SPD-M6-V1 proton NMR chemical shifts in ppm 
 
Residue H Hα Hβ Hγ Hδ Hε 
Val-16 8.062 3.934 1.953 0.845   
Cys-17 7.993 4.649 2.363/2.442    
Asp-18 8.459 4.162 2.493/2.617    
Phe-19 8.447 4.103 2.895/3.011  6.705 6.483 
UAA-20 7.952 4.199 3.540/3.646    
Cys-21 8.340 4.743 2.931    
Tyr-22 8.710 4.304 2.630/2.979  7.401 6.709 
Trp-23 7.739 4.315 2.643  7.813 6.522 
(ε3) 
9.495 
(ε1) 
Asn-24 7.848 4.582 2.65    
Asp-25       
Leu-26 7.839 3.893 1.405 1.516   
UAA-27 7.683 4.216 4.003/4.081    
Gly-28 7.644 3.777 3.894    
Tyr-29 7.817 4.565 2.666    
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Table II - S4 – Structural statistics of twenty lowest energy structures of SPD-M6-
V1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Distance constraints  
Intra residue (i = j) 40 
Sequential (i–j = 1) 32 
Medium range [1 < |i–j| ≤ 4] 29 
Total 101 
  
Angle constraints  ϕ, ψ constraints 24 
  
Deviation from mean structure (RMSD)  
All backbone atoms 0.20 Å 
All heavy atoms 0.87 Å 
  
Ramachandran plot for the mean structure  
% residues in the most favored region 33.3 
% residues in the additionally allowed region 66.7 
% residues in the generously allowed region 0.0 
% residues in the disallowed region 0.0 
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Table II - S5 – CYANA library file for the linker 
 
RESIDUE   XUN      8   28    3   27 
1 OMEGA     0    0    0.0000 -O   -C    N    H 
2 PHI       0    0    0.0000 -C    N    CA   C 
3 CHI1      0    0    0.0000  N    CA   CB   HB2  O5 
4 CHI2      0    0    0.0000  CA   CB   CG   N1  O5 
5 CHI3      0    0    0.0000  CB   CG   N1   N2 O5 
6 CHI4      0    0    0.0000  CD   CE   CZ   O5 O5 
7 CHI5      0    0    0.0000  CE   CZ   O5   O5 O5 
8 PSI       0    0    0.0000  N    CA   C   +N 
1 C     C_BYL    0    0.0000    0.0000    0.0000    0.0000 -O    N 
2 O     O_BYL    0    0.0000   -0.6700    0.0000   -1.0322 -C 
3 N     N_AMI    0    0.0000    1.3290    0.0000    0.0000 -C    H    CA 
4 H     H_AMI    0    0.0000    1.8069   -0.0007    0.8553  N 
5 CA    C_ALI    0    0.0000    2.0929   -0.0011   -1.2414  N    HA   CB   C 
6 HA    H_ALI    0    0.0000    2.7479   -0.8605   -1.2295  CA 
7 CB    C_ALI    0    0.0000    1.1392   -0.1380   -2.4612  CA   HB2  HB3  CG 
8 HB2   H_ALI    0    0.0000    0.1585    0.2327   -2.1632  CB   -    -    -    QB 
9 HB3   H_ALI    0    0.0000    1.1625   -1.1929   -2.7339  CB   -    -    -    QB 
10 QB   PSEUD    0    0.0000    0.6605   -0.4800   -2.44860 
11 CG   C_ALI    0    0.0000    1.5735    0.6318   -3.7403  CB   HG2  HG3  N1 
12 HG2  H_ALI    0    0.0000    1.6155    1.6991   -3.5217  CG   -    -    -    QG 
13 HG3  H_ALI    0    0.0000    2.5045    0.1736   -4.0734  CG   -    -    -    QG 
14 QG   PSEUD    0    0.0000    2.0598    0.9366   -3.79707 
15 N1   N_AMI    0    0.0000    0.4964    0.3682   -4.9496  CG   CD   N2 
16 CD   C_ARO    0    0.0000    0.1424    0.6380   -6.3514  N1   HD   CE 
17 HD   H_ARO    0    0.0000    0.7249    1.1857   -7.0924  CD 
18 CE   C_ARO    0    0.0000   -1.2008   -0.0088   -6.5356  CD   N3   CZ 
19 N3   N_AMO    0    0.0000   -1.5724   -0.5758   -5.4308  CE   N2 
20 N2   N_AMO    0    0.0000   -0.6727   -0.3850   -4.5762  N1   N3 
21 CZ   C_ALI    0    0.0000   -2.0142   -0.0017   -7.8431  CE   HZ2  HZ3  O5 
22 HZ2  H_ALI    0    0.0000   -2.0363    1.0090   -8.2516  CZ   -    -    -    QZ 
23 HZ3  H_ALI    0    0.0000   -1.5522   -0.7495   -8.4875  CZ   -    -    -    QZ 
24 QZ   PSEUD    0    0.0000   -1.7946    0.1301   -8.36898 
25 O5   O_HYD    0    0.0000   -3.3496   -0.4375   -7.5771  CZ 
26 C    C_BYL    0    0.0000    2.9378    1.2621   -1.3672  CA   O   +N 
27 O    O_BYL    0    0.0000    2.4397    2.3166   -1.7634  C 
28 N    N_AMI    0    0.0000    4.2169    1.1488   -1.0273  C 
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Figure II - S1. Specific Surface Binding  
A: Displayed peptides were reacted with SCy5-alkyne and run on a polyacrylamide gel 
after normalization by BCA assay. Fluorescence was quantified using the Odyssey CLx 
imager in the 700 nm channel. B: W23A and F19A do not exhibit appreciable binding to 
MDM2 as quantified by flow cytometry, despite similar levels of surface display (A). 
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Figure II - S2. Logo plots for pooled sequences (A) and i, i+5 containing sequences 
(B). 
 
 
Figure II - S3. Population level and individual clone analysis by flow cytometry.  
Histograms are shown for approx. 12,000 events for samples labeled with 0.25 nM 
MDM2-GST (A) and 25 nM MDM2-GST (B). No selection is the original library containing 
3 x 108  transformants. MACS refers to the population obtained from one round of positive 
selection with magnetic beads. FACS 1, 3, 5, 7 refer to the populations sorted after 1, 3, 
5, and 7 rounds of fluorescence-based sorting. The even-numbered sorted populations 
are not shown here for clarity. 
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Figure II - S4. MDM2 truncate and MDM2-GST cell-surface binding.  
(A) MDM2(10-118)-biotin was titrated against surface displayed peptide (SPD-M0-E(-2) 
or SPD-M6-V1) and labelled with Streptavidin-Alexafluor-647 prior to flow cytometric 
analysis. (B) Clones from earlier sorting rounds were also characterized for binding affinity 
with MDM2-GST to validate sorting for improvements. Sequences YSC… and SCG… 
were obtained from the resultant library of MACS, and sequence NYD… was obtained 
from 2 subsequent rounds of FACS. 
 
 
Figure II - S5. Analysis of clones after round 7 of FACS.  
After 1 round of MACS and 7 rounds of FACS, 3200 transformants were obtained, and 
40 individual colonies were sequenced. A. The distribution of sequences shows that 13 
of these colonies are SPD-M6-V1, motivating the selection of this sequence for further 
study. A large fraction of clones showed cysteines at i,i+4 (green) and i,i+5 (red) positions. 
B. The apparent binding affinity on the cell surface of 6 clones from the last sort. C. The 
measured Kd values of these 6 clones and SPD-M6-V1 all show similar improvement over 
SPD-M0-E(-2).   
  76 
 
 
Figure II - S6. Solution Phase Peptide Binding Affinity.  
(A) BLI sensograms for the on-phase (left) and off-phase (right) of peptides binding to 
immobilized MDM2(10-118). (B) Representative peptide analysis showing on-phase and 
off-phase data points fitted to an association equation (left) and dissociation equation 
(right) respectively in Graphpad Prism v. 6. Curves with significant instrument drift were 
eliminated from analyses. 
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Figure II - S7. Secondary structure measurements  
(A) Grouped circular dichroism (CD) spectra for peptides presented with (solid line) and 
without (dotted line) stabilization. (B) CD spectra for SPD-M6-V1 and reaction variants. 
(C) aH chemical shift deviation from random coil values of SPD-M6-V1. The negative 
deviation of residues indicates a-helix structure. 
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Figure II - S8. NMR Characterization.  
(A) 1H-1H homonuclear 2D TOCSY spectrum showing amide fingerprint region of SPD-
M6-V1. (B) Depiction of amino acid connectivity as inferred from NOESY spectra. (C) 
Histogram of interactions at each amino acid position of SPD-M6-V1 as estimated from 
NOESY and TOCSY experiments. 
 
 
 
 
  79 
 
 
Figure II - S9. Surface Exendin-4 display and binding.  
20 nM anti-exendin antibody was incubated with bacterial surface displayed exendin-4 
peptide and labelled with anti-mouse-Alexafluor-647 secondary antibody prior to flow 
cytometric analysis (red). Negative cells were stained with isotype control antibody and 
anti-mouse Alexafluor-647 secondary antibody (cyan). 
 
 
Figure II - S10. eCPX Modifications.  
Reducing, denaturing protein gel of eCPX constructs post-SCy5-alkyne reaction. The 
starting eCPX protein exhibits low, but specific signal despite not displaying a peptide. 
(A) Mutation of the 3 non-start methionine residues results in abrogation of this signal. 
Genetic incorporation of the SPD-M0-E(-2) peptide restores high levels of signal. (B) DNA 
sequence of the peptide region of the primer used to encode the randomized library. (C) 
plasmid map of the eCPX gene cloned into pQE80L showing restriction sites 
EcoRI/HindIII for gene insertion, SfiI sites (used to introduce the peptide sequences), and 
the M to L mutation sites. The sequence located N-terminally of P53-like peptide is 
cleaved prior to translocation into the outer membrane, resulting in display of the peptide 
as an N-terminal fusion to eCPX. 
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Figure II - S11. Surface-solution correlations.  
Stabilization improves the correlation between affinity measured in solution (BLI affinity) 
and on the bacterial surface (BSD affinity). For non-stabilized peptides, the slope of the 
best-fit line is not significantly different from 0 (p = 0.16, t = 1.63, df = 5) whereas a positive 
slope is obtained for stabilized peptides (p = 0.018, t = 3.47, df =5) (n = 3 independent 
trials per data point). 
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Supplementary modeling discussion 
To calculate the extent of surface reaction, we modelled the system using the equations 
implemented below in MATLAB v. 2018a. Because mass spectrometry cannot be used 
to independently identify species B and C, the stabilized bacteria underwent a 2nd reaction 
with azide- or alkyne-dyes. Species A and B react with alkyne dyes, while species B and 
D react with azide-dyes. By analyzing the peptide band by SDS-PAGE and normalizing 
to the total peptide in the eCPX-peptide band (because ‘C’ does not react with either dye), 
the fraction of C could be calculated from the data set. 
 A, surface-displayed peptide; B, singly-reacted; C, stabilized peptide; D, two linker-reacted 
peptide; L, linker k' is rate of reaction of one site with L. k(, rate of stabilization d[A]dt = 	−k'[L] ∙ [A] d[B]dt = 	 k'[L] ∙ [A] − k([B] − k'[L] ∙ [B] d[C]dt = k([B] d[D]dt = k'[L] ∙ [B] 
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Modelled rates: k' = 1.8;						k( = 9 
Initial conditions: A(0) = 42.6; 					B(0) = 0; 					C(0) = 0; 					D(0) = 0 
 
The parameters were varied to test the robustness of the predictions. The ratios of 
the modelled azide signal from species B and D at each concentration (e.g. the azide 
signal at 100 μM alkyne species to the azide signal at 5 μM alkyne species) is relatively 
insensitive to the values of the modelled rates and accurately maps to the experimental 
found signal, as long as the ratio of k( to k'	is between 3 and 6 (currently 5) and that the 
modelled end-point corresponds to the experimentally found fraction of displayed azides 
reacted. 
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Abstract 
 
Directed evolution has seen numerous impactful applications in enzyme technology, 
antibody engineering, other biomolecular recognition systems, and industrial microbe 
development. When paired when display techniques, such as with phage, bacteria, and 
yeast, it affords a high-throughput way of screening diverse libraries of biomolecules. We 
have previously developed a method to screen stapled peptide libraries on the surface of 
E. coli to discover propargyl ether click-stabilized inhibitors of the p53-MDM2 interaction. 
The modular nature of the double-click peptide stapling strategy invites introducing 
physicochemical diversity into the linker to improve or add properties like cell penetrance, 
fluorescence, protease stability, and binding affinity by increasing contact area. In this 
work, we introduce diversity into p53-like click-stabilized peptides by using an all-
hydrocarbon aliphatic staple, a rigid benzene staple, and an extended linker containing a 
functionalizable amine group. We conducted one round of magnetic sorting and 4 rounds 
of fluorescence-activated cells sorting (FACS) to generate enriched libraries for each 
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unique linker. Flow cytometric analysis of sorted populations revealed affinity 
improvements in all linker libraries, including those with initially poor binding. Extensive 
deep sequencing of each library after each round elucidated sequence-linker 
dependencies and trends. This work represents the application of chemically diverse 
linker libraries for the high throughput screening of MDM2-binding stapled peptides.  
 
Introduction 
Targeting protein-protein interactions (PPIs) can result in therapeutic outcomes, but due 
to the large surface area over which PPIs occur, have largely failed to be effectively 
inhibited by small molecule drugs1. They are involved in all disease states and 
dysfunctional PPIs, due to mutation or epigenetic changes, are found in many cancers. A 
few prominent examples of PPIs include p53-MDM22, Bim-BCL23, and SOS1-KRAS4, two 
of which have avoided clinical inhibition by small molecules, with venetoclax only recently 
receiving FDA approval for targeting BCL25. Much larger proteins, like antibodies and 
molecules based off antibodies like scFvs, affibodies, nanobodies, and Fab fragments, 
while offering highly specific and potent target engagement, are largely restricted to 
extracellular binding, with engagement of cytoplasmic targets only reported in a few 
cases6,7, with no clear understanding of the targeting mechanism. In contrast, stapled 
peptides have been developed against a range of cytoplasmic and extracellular targets4,8–
12. It is well understood that the linker size and charge play a large role in determining 
intracellular access13–16 and several assays have been developed to determine 
cytoplasmic peptide localization17–19.  
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 Directed evolution has been used to screen libraries of biomolecules, including 
peptides, for high affinity binding. Examples include phage display20, bacterial21 and yeast 
surface display22, and mRNA display23, and each approach has its relative merits and 
disadvantages. All of these methods couple genotype (encoding nucleic acid sequence) 
to phenotype (protein binding), making selection by cellular sorting or panning followed 
by sequencing possible. Post-sort stapling was used to develop ATSP-704124, the 
precursor to the ALRN-6924, an MDM2 inhibitor that is currently in clinical trials. However, 
it is also understood that inappropriate stapling location and flanking residue identity can 
result in binding losses25, making post-selection stapling optimization time-consuming 
and expensive, as each option has to be synthesized by solid phase peptide synthesis 
(SPPS) and characterized for potency11.  
There is a nascent effort underway to select peptides that have been stapled while 
displayed, that is, prior to sorting, so that physicochemical changes conferred by stapling 
interact with amino acid residue identity in a synergistic manner. Heinis and coworkers 
displayed cysteine-bridged alpha helices with bis-bromo containing linkers using phage 
display to discover beta-catenin binders9. Araghi et al. used one-bead-one-compound 
technology to screen a small library of all-hydrocarbon olefin metathesis stapled peptides 
against Bcl-226 and used mass spectrometry to decode peptides. Our lab has developed 
SPEED, an approach using azidohomoalanine incorporation in E. coli to display bio-
orthogonally double-clicked stabilized peptides and applied it to discover potent inhibitors 
of the p53-MDM2 interaction27. In this earlier work, we generated a library of propargyl 
ether (1) stabilized peptides and conducted several rounds of magnetic and fluorescence-
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based sorting. We found a lead compound, SPD-M6-V1, that contained two cysteines 
involved in a disulfide bond, an affinity-enhancing motif that notably could not arise from 
a cysteine-modifying strategy. 
Despite the high affinity of bacterially-displayed propargyl ether-stabilized p53-like 
sequence28 and even higher affinity of SPD-M6-V1 (Kd values of 15 nM and 1.7 nM 
respectively), other staple linkers could increase or decrease binding through 
unpredictable and significant effects on helicity and contacts with MDM2. The role of 
staple length and rigidity has been previously investigated by Zhang et al. for double-click 
stabilization of GLP1R ligands, finding a modest loss in affinity for 1,3-diethynylbenzene-
stabilized GLP1 and exendin-4 and no significant loss in affinity for AlexaFluor680-
conjugated linker stabilized molecules compared to propargyl ether29. Lau and coworkers 
have conducted extensive comparison studies with linear and aromatic hydrocarbon bis-
alkyne linkers of different lengths and found ~2-fold loss in affinity for a phage-evolved 
sequence when stapled with the rigid 1,3-diethynylbenzene staple vs. a linear molecule30. 
Conjugating a mono-arginine, bi-arginine, or tri-arginine motif to the staple led to 
decreases in measured affinity as well31. Furthermore, Kale et al. screened large phage 
libraries with a variety of cysteine-modifying linkers to study the importance of staple 
length and staple dependence on sequence32. As we have found disulfide bond formation 
important for potent MDM2 binding27, we were motivated to study directed evolution with 
diverse staples in a bioorthogonal manner (i.e. preserving the role of cysteines and other 
residues) to understand how linker-sequence synergy results in affinity improvements. 
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Results 
 
P53-like sequence and SPD-M6-V1 are poor MDM2 binders with diverse double-
click linkers 
Using the on-surface optimized click stabilization method from our previous work27, we 
stabilized the p53-like sequence with propargyl ether (1), 1,6-heptadiyne (2), 1,3-
diethynylbenzene (3), and an amine-functionalizable extended linker (4) first developed 
for peptide imaging agent synthesis29,33 (Figure III - 1A). After stabilization, bacteria were 
labeled with fluorescent MDM2-GST and analyzed by flow cytometry. This revealed 
significant loss in signal for the p53-like sequence reacted with (2) compared to 
unreacted, and even larger losses for (3) and (4) (Figure III - 1B, left). For the propargyl 
ether-evolved SPD-M6-V1 sequence, we observed no loss in signal for (2), which is 
consistent with the similar but not identical structures, with a substitution of an oxygen for 
a carbon. We did however observe large losses in binding for (4) and especially (3) for 
SPD-M6-V1 (Figure III - 1B, right). 
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Figure III - 1. Structures and binding histograms of previously reported sequences 
(A) structures of stabilizing bis-alkyne linkers used in this paper, (1), propargyl ether, (2), 
1,6-heptadiyne, (3), 1,3-diethynylbenzene, (4), amine functionalizable extended linker. 
(B) Flow cytometry histograms of bacteria displaying bis-alkyne linker stabilized p53-like 
peptide (PLP, left) or SPD-M6-V1 (right).  
 
Staple location strongly influences binding affinity for the p53-like sequence 
The construction of our bacterial surface libraries allows the pooling and decoding of 
libraries containing many possible staple locations. To establish the importance of 
stapling location, we modified the starting p53-based sequence (PLP) with alternative 
stapling locations, 1-8 and 6-13. We selected these positions based on our docked 
structure of SPD-M6-V1 binding to MDM227 (Figure III – 2A), hypothesizing that the 1-8 
location would be staple-permissive, while the stapling at the 6-13 location would 
abrogate binding. Indeed, affinity determination on the bacterial cell surface (Figure III – 
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2B) confirmed that stapling dramatically worsens affinity at the 6-13 position (Table III – 
1). We have shown that for the PLP sequence in particular, bacterial surface 
measurements underestimate stapling affinity gains27. and thus, the “true” in-solution 
affinity loss upon stapling PLP(6-13) is likely greater the reported ~6 fold (Table III -1).  
 
Figure III - 2. Staple scan locations and measured affinity.  
A) Based on our calculated structure of SPD-M6-V1 bound to MDM227, two additional 
pairs of locations (1-8 and 6-13) were chosen for mutagenesis to methionine, AHA 
replacement, and stapling. Stapling residues are highlighted in red. In PLP (left), residues 
4 and 11 were chosen as the stabilization sites, as well was in the library based on PLP27. 
Analysis of the structure suggests PLP and PLP(1-8) would exhibit minimal clashes upon 
stapling with propargyl ether, whereas stapled PLP(6-13) is expected to exhibit steric 
clashes with MDM2. (B) Measurement of binding affinity on the bacterial cell surface 
corroborates the stapling location clash hypothesis, with PLP and PLP(1-8) exhibiting 
minimal loss in affinity upon stapling with propargyl ether (see Table III – 1 for values), 
but PLP(6-13) exhibiting significant affinity loss. (C) Total signals from PLP and stabilized 
PLP, showing a marked decrease in signal upon stabilization despite similar affinity 
(Table III – 1). 
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Table III - 1. Affinity data for chosen alternate stapling locations.  
Peptides with stapled with propargyl ether and X in the sequence represents 
azidohomoalanine. 
Name Sequence Non-stabilized Kd Stabilized Kd 
PLP ETFXDLWRLLXEN 15 ± 2.5 nM 27 ± 3.8 nM 
PLP(1-8) XTFSDLWXLLPEN 23 ± 3.5 nM 23± 4.3 nM 
PLP(6-13) ETFSDMWRLLPEM 28 ± 4.3 nM 180 ± 42 nM 
 
Directed evolution of a randomized i,i+7 azidohomoalanine library yields affinity-
improved binders with diverse linkers 
Because of poor MDM2 binding after stabilization with linkers (2), (3), and (4) of p53-like 
and SPD-M6-V1 sequences, we evolved randomized peptides displayed with eCPX 
based on the p53 binding sequence to MDM2. Library construction was carried out as 
reported previously27, and briefly, the three critical MDM2-binding residues (F19, W23, 
L26) as well as the two Met sites for stabilization (X20, X27) were kept fixed. All other 
sites were randomized by an NNC codon scheme permitting 15 possible amino acids and 
no stop codons at each position. Peptides were displayed as N-terminal fusions to the 
met-removed eCPX scaffold expressed in the pQE80L vector27. Libraries were stabilized 
and sorted first by MACS and then by 4 serial rounds of FACS. In between rounds, cells 
were lysed, DNA extracted, and fresh cells were transformed. Freshly transformed 
libraries were grown up, induced, and reacted with a given linker (see methods), or no 
linker at all (0) as a negative control.  
Flow cytometric analysis of sorted populations revealed that binders were enriched 
in all three linker and no linker populations (Figure III - 3). However, the magnitude of 
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binding improvements depended strongly on linker identity. No linker (0) and 1,6-
heptadiyne (2) showed most improvement, and this was apparent as early as the first 
round of sorting (by MACS, Figure III - 3A, 3B). 1,3-diethynylbenzene (3) showed the 
most minimal enrichment, though sorted populations after MACS and after 4 rounds of 
FACS could still be discerned from the unsorted population (Figure III - 3C). The extended 
linker molecule (4) showed an intermediate phenotype improvement with a less evident 
MACS shift (Figure III - 3D).  
 
Figure III - 3. Flow cytometry histograms of populations differentially stabilized. 
Populations were stabilized with no linker (0; A) or different linkers (2, 3, 4; B-D). In all 
four subplots, MACS and FACS enrichment are evident but the magnitude depends on 
the linker, with 0 and 2 showing the most improvement in both MACS and after 4 rounds 
of FACS. 3 shows the least FACS improvement, while 4 shows a modest shift. A 
population shift similar to the magnitudes in (A) and (B) is apparent for selections carried 
out with propargyl ether as reported in our previous work (Figure 2A)27. 
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Mixed reaction analysis reveals linker identity dependencies 
As the traditional approach in developing high affinity stapled peptides involves non-
stabilized peptide display and post-screen stapling34,35, we evaluated the impact of 
stapling on MDM2 binding of libraries evolved with and without stapling. We also tested 
the impact of neglecting to staple on a library screened with the least binding-improved 
staple, 1,3-diethynylbenzene (3). These results showed that for peptides evolved with 
1,3-diethynylbenzene stapling, a lack of stapling actually conferred higher binding than 
with stapling (Figure III - 4A, 4C). Importantly though, the converse test, in which peptides 
evolved without stapling were evaluated, post-screening 1,3-diethynylbenzene 
stabilization conferred the poorest binding properties (Figure III - 4D). In other words, the 
1,3-diethynnylbenzene staple reduces affinity of the peptide even with evolution, this 
‘penalty’ in binding is reduced relative to peptides evolved without stapling. This is 
consistent with the idea that given a need for stabilization (for protease stability, cell 
penetration, in vivo circulation, etc.), it is preferable to staple pre-screen (Figure III - 4A) 
than post-screen (Figure III - 4D).  
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Figure III - 4. Analysis of binding for peptide libraries with or without 1,3-
diethynylbenzene stapling.  
(A) “concordant, no reaction”, where displayed peptides evolved without reaction are also 
not reacted, showing high improvement. (B) “concordant with reaction,” where displayed 
peptides evolved with (3) are reacted with (3), showing modest improvement. (C) 
“discordant, no reaction”, where peptides evolved with (3) are not reacted, showing 
similarly high improvement. (D) “discordant with reaction,” where peptides evolved 
without (3) are reacted, showing the poorest binding and little separation between 
unsorted and most sorted population. 
 
 
Affinity analysis of individual sequences shows linker-specific and linker-
independent evolution  
We sequenced several clones from each final library (following MACS and 4 rounds of 
FACS) and surface-expressed peptide stabilized with each linker (see methods) and 
titrated three concentrations of MDM2-GST to assess target affinity. 1,3-
Discordant,
reaction
Discordant,
no reaction
Signal
Co
un
t
Co
un
t
Concordant,
no reaction
(0) + (0)
(0) + (3)(3) + (0)
Concordant,
reaction
(3) + (3)
A B
C D
  101 
diethynylbenzene (3) reacted peptides uniformly showed decreased signal relative to the 
other linkers, but in a sequence-dependent manner (Figure III - 5). In all cases except for 
the peptide evolved and stabilized with the functionalizable linker (4), Figure III - 5D, 
peptides exhibited highest signal without reaction. We also observed significant 
decreases in signal for known binder PLP upon stapling even with saturating 
concentrations of MDM2 (Figure III – 2C) and are currently working on determining the 
cause. This may be a difficult-to-avoid consequence of a reaction with multiple side-
products (see Figure III - 7 and modeling methods), and we hypothesize that the double-
reacted peptide products may compromise binding and reduce signal.  
 Because of the mix of shared ‘target-specific’ mutations (e.g. i,i+5 cysteines) 
versus target specific contributions, it is difficult to generate concrete conclusions from 
isolated examples. Therefore, we sought to use next-generation sequencing (NGS) of the 
libraries to analyze the enrichment in a high-throughput manner. 
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Figure III - 5. Binding analyses of 4 peptides isolated after 4 rounds of FACS from 
each library.  
(A) CVTFMCYWGDLII, from evolution with no peptide stabilization, exhibits highest signal 
without stabilization and depressed signal when stabilized with either (3) or (4). (B) 
CFTFMCYWSDLMGN from evolution with stabilization with (2), shows slightly higher 
signal without stabilization but comparable signals for (2) and (4), with the greatest 
decrease for (3). (C) CITFMCFWGNLMAD, from evolution with stabilization with (3), was 
an unexpected poor binder with (3) and showed best signal without stabilization (D). 
CIFFMCFWNDLMGY, from evolution with (4), interestingly exhibits highest binding signal 
with (4), but decreased affinity relative to (0), comparing the 40 nM labeling to the 160 nM 
labeling signals. Reaction with (3) indicates that this sequence is a poor 1,3-
diethynylbenzene binder, supporting the idea that evolution in the desired staple context 
is important to discover good binders. 
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Deep sequencing reveals linker-specific and broader conservation trends 
We performed deep sequencing for each linker library for each round of selection to 
uncover sequence patterns using the Illumina NovaSeq platform and obtained between 
2 million – 12 million reads per library. After quality control and barcode assignment, we 
generated amino acid logo plots36 for the most abundant sequences from the 4th round of 
FACS for all linker libraries (Figure III - 6A) and computed frequencies of unique 
sequences (Figure III - 6B). All libraries except for those evolved with 1,3-
diethynylbenzene (3) showed clear enrichment patterns, with the no reaction library being 
glycine-rich and consistently losing the second stabilization site. We speculate that 
sequences that undergo the M12I mutation may be better displayers, as AHA 
incorporation at two sites modestly reduces display level27. 1,6-heptadiyne (2) sequences 
show strong and clear enrichment of fan N-terminal i,i+5 cysteines motif, suggesting 
disulfide bond formation. The functionalizable linker (4), in contrast, shows position-
specific preference for serine and asparagine residues with a significant minority of 
peptides containing i,i+5 cysteines. Sequences evolved with 1,3-diethynylbenzene (3) 
reaction show very little evidence of residue conservation (Figure III - 6A), and analysis 
of the frequencies of 300 peptides reveals many more low abundance peptides than any 
of the other libraries, indicating weak selection pressure (Figure III - 6B). In addition to 
these linker-specific trends, a number of conserved residues were common to no reaction 
(0), 1,6-heptadiyne (2), and the functionalizable linker (4), such as D10 and Y/F7, with a 
clear bias against Y7 for the functionalizable linker. Put together, the deep sequencing of 
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sorted libraries identified both linker-specific and linker-agnostic sequence patterns for 
MDM2 binding. 
 
Figure III - 6. Deep sequencing analysis. 
(A) Logo plots for the 300 most abundant clones after four rounds of FACS. Starred 
residues (F4, M5, W8, L11) were fixed in the generated library. Differential conservation 
patterns are observed for all three linkers and lack of linker, with loss of the methionine 
at position 12 without the linker (0), consistent with not requiring AHA substitution at that 
site. An i,i+5 cysteine motif was very prominent for (2), indicating a role for a disulfide 
bond in binding. (3) showed very little sequence conservation at any site, indicating low 
efficiency in sorting or lack of binding enhancement conferred by specific amino acids. 
This is consistent with the relatively poor binding for populations and individual clones 
observed. (B) Ranked frequency plot of 300 sequences present in each library with 
zoomed-in inset. This shows that for evolution done with (0), (1), (2), and especially (4), 
a few sequences dominate the population, but for (3), there are many sequences that 
appear only once, indicating lack of conservation as also shown in Figure III - 6A.  
 
Reaction analysis shows inefficient stabilization for 1,3-diethynylbenzene (3) 
We had previously optimized reaction conditions, including Cu2+ concentration, chelator 
identity and concentration, and sodium ascorbate (reducing agent) concentration, bis-
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alkyne concentration using propargyl ether as the linker27. Other bis-alkyne linkers have 
been reported to react with similar kinetics in solution, prompting the use of identical 
conditions for sorts30,31. However, the generally poor binding to MDM2 observed at the 
library and clonal level for 1,3-diethynylbenzene (3) stabilized peptides (Figure III – 3C, 
III - 3D) led us to investigate stabilization efficiency for surface displayed p53-like peptide. 
Cell lysates following click-stabilization were run on a gel after reaction with one of two 
reactive dyes to probe unreacted azide sites (SCy5-alkyne, Figure III - 7A, left) or 
unreacted alkynes from incomplete peptide stapling (SCy5.5-azide, Figure III - 7A, right). 
Analysis (using a computational approach, see methods) revealed the virtual lack of 
stabilized peptides when reaction was carried out with 1,3-diethynylbenzene (3). 
Differential equation modeling, fit to the azide- and alkyne- reactivity dataset (Figure III - 
7A), showed that propargyl ether and 1,3-diethynylbenzene react very differently, with 
propargyl ether favoring the stabilized species but 1,3-diethynylbenzene favoring the two-
reacted side product. In fact, due to incomplete reaction (Figure III - 7B), changing the 
concentration of 1,3-diethynylbenzene alone to favor more stabilization would not improve 
the fraction reacted. These results explain the lack of enrichment and sequence 
consensus in the 1,3-diethynylbenzene sorted libraries. Other experimental approaches, 
like decreasing or changing the catalyst, or decreasing reductant concentrations might 
reveal improved conditions for reaction with (3). For the other two linkers studied in this 
paper, inferred fraction reacted and fraction stabilized values are consistent with 
propargyl ether-like reactivity and are suitable for stabilizing peptides on the surface of 
bacteria. 
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Figure III - 7. Reactivity and modeling of stabilization on the bacterial surface. 
(A) Quantification of free azides (left) and free alkynes (right) on the bacterial surface 
following click-stabilization with different linkers. Free azides result from AHA 
incorporation into the peptide and the maximum signal is given by the result from (0). Free 
alkynes result from incomplete stabilization, i.e. when only one of the alkyne moieties on 
the staple reacts with a surface displayed molecule. The highlighted band corresponds to 
eCPX-p53-like sequence. (B) Model fitting to the azide and alkyne quantification reveals 
fraction reacted AHA residues and fraction stabilized peptides. (C) Model trajectories for 
propargyl ether (1), a successful click-stabilizer and for 1,3-diethynylbenzene (3), which 
primarily results in two molecules of (3) reacting per peptide. 
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Discussion 
Stapled peptides have been developed as powerful modulators of traditionally 
“undruggable” protein-protein interactions.  Due to the slow kinetics of peptide cellular 
uptake relative to lipophilic small molecule drugs, only a small amount of an administered 
peptide typically accesses the cytoplasm, and thus the target affinity must be very high to 
observe efficacy. Linker identity has been widely reported to influence the affinity and 
target engagement of stapled peptides29–31 as well as bioavailability in subcutaneously 
administered imaging agents33. This could be due to numerous factors, like target 
engagement11,24,37 by the staple contributing to enthalpic gains, or protease 
resistance33,38. Of course, a stapled peptide’s sequence and accompanying 
characteristics such as conformation, charge, and ability to form intermolecular bonds 
with the target strongly impact its drug-like behavior as well. Staple location matters as 
well; exhaustive staple location scanning is typically carried out to identify the best two 
sites11 and we have shown the importance of avoiding the 6-13 site (Figure III – 2B). 
Despite the preponderance of directed evolution techniques to find high affinity binding 
sequences, there are no reports of simultaneously evolving sequence and linker. We 
hypothesized that sequence and linker synergize and that the optimum linker for a 
particular sequence is sequence-dependent. To test this, we conducted multiple rounds 
of sorting on a randomized MDM-binding library with different linkers to discover 
synergies. This was motivated by the fact that in the p53-MDM2 system, we tested a p53 
mimic and a propargyl ether-evolved lead compound SPD-M6-V1 and found that they 
bound to MDM2 in a highly linker-dependent manner (Figure III - 1).  
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In this work, we characterized the reaction between various linkers and bacterially 
displayed peptide and found that 1,3-diethynylbenzene reacts poorly and does not result 
in stapling. Thus, all screens with libraries reacted with 1,3-diethynylbenzene likely 
contained peptides with predominantly double-reacted product (with two linkers per 
peptide). This potentially explains why less selection was observed when evolved with 
1,3-diethynylbenzene (Figure III - 3) and all individual clones showed poor binding upon 
reaction with 1,3-diethynylbenzene (Figure III - 5). The linker must undergo efficient 
reaction and cross-linking to enable proper sorting. 
The other two linkers for which libraries were evolved showed sufficient cross-
linking efficiency. Deep sequencing has proved to be a powerful tool to understand sorting 
and evolution and we applied this technology to understand our libraries. Consistent with 
the lack of optimal reactivity, 1,3-diethynylbenzene showed poor enrichment and limited 
selection. Most interestingly, deep sequencing revealed unique residue conservation 
fingerprints in evolved peptides both non-stabilized and stabilized with 1,6-heptadiyne (3), 
propargyl ether (1, data in chapter II of this dissertation), and the functionalizable linker 
(4) in Figure III - 6. Specifically, glycine residues at several sites (G1, G3, G6) and 
methionine loss at position 12 are favored in the no reaction evolution. Conservation of 
both I,i+4 and i, i+5 motifs is present in propargyl ether libraries27 whereas the i, i+5 
cysteine motif is strictly conserved for libraries stabilized with 1,6-heptadiyne. The specific 
sequence GLDFMSFWSGLMNN was highly conserved in evolution with the 
functionalizable linker, and work is ongoing in the lab to elucidate the biophysical 
properties of this molecule. At position 7, different linkers have preferences for either Y 
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or F only, with propargyl ether and no reaction favoring Y, heptadiyne and 1,3 
diethynylbenzene having roughly equal abundance of Y or F, and functionalizable linker 
favoring F nearly exclusively. There are a few pan-linker conservation trends as well: D10 
and N-terminal i, i+5 motifs are abundant in every final round sort library.  
These analyses largely support the idea that the linker identity and sequence 
should not be developed independently of one other; rather, a linker should first be 
selected based on desired application. Some specific examples of linker choice are a 
fluorophore-containing linker for imaging applications29,31,33, a polyarginine motif for 
cellular penetration15, or others for protease stability. These linkers then would be reacted 
with a randomized library, and selections carried out with the presence of the particular 
linker. This approach would avoid the need to do expensive, post-screen optimization of 
sequence to tolerate the linker.  
Co-crystal structures of stapled peptides with their targets have identified linker-
protein contacts37 and therefore it makes sense that linker identity can affect binding and 
moreover, synergy between linker and sequence can enforce the binding conformation 
with higher affinity. Additionally, machine learning approaches are amenable to the 
abundance of data from next generation sequencing (>108 sequences). Future work in 
our lab will involve use of deep learning methods to identify sequences with linker-specific 
and linker-agnostic binding followed by synthesis, biophysical characterization, and 
efficacy studies. 
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Methods 
Materials 
All chemicals were purchased from Sigma Aldrich unless noted below. PBS was obtained 
from Invitrogen (1X).  The functionalizable bis-alkyne linker (4) was synthesized in-house 
according to the procedure in ref. 29 which is reproduced in the Appendix of this 
dissertation. All DNA oligos were purchased from Integrated DNA Technologies 
(Coralville, IA), and all restriction enzymes were purchased from New England Biolabs 
(Ipswich, MA). The eCPX gene in pB33eCPX (a gift from P.S Daugherty, Addgene 
plasmid # 23336) was modified as described in ref. 27 to avoid undesired methionine 
substitution at non-peptide sites. The Met auxotrophic E. coli strain TYJV2 was a 
generous gift from J. van Deventer. Electrocompetent cells for transformation and library 
generation were made according to the procedure described in ref. 39. MDM2-GST for 
sorting and analysis was recombinantly expressed and purified as described in ref. 40. 
Staple mutants 
Staple mutants PLP(1-8) and PLP(6-13)  were generated using primers 
ACTTCCGTAGCTGGCCAGTCTGGCCAGATGACCTTTAGCGATCTGTGGATGCTGC
TGCCGGAAAACGGCGGTGGCAGCGGAGGGCAGTCTGGGCAGTCTG and 
ACTTCCGTAGCTGGCCAGTCTGGCCAGGAAACCTTTAGCGATATGTGGCGCCTGC
TGCCGGAAATGGGCGGTGGCAGCGGAGGGCAGTCTGGGCAGTCTG respectively, 
using the loop insertion procedure on the eCPX(-met) template27 as described by Getz 
et al.41 
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Library generation 
A methionine-free version of eCPX (except for the start codon) was used as a PCR 
template for generating the NNC library as described in ref. 27. After digestion and 
ligation, the library was transformed into electrocompetent Met auxotrophic TYJV2 E. coli 
achieving a library size of approximately 3 x 108 members.  
 
Library expression and on-surface peptide reaction 
As discussed in ref. 27, generated libraries or single clones for characterization were 
grown in M9 medium containing 20 amino acids (with 10x oversampling if a library). Upon 
reaching OD600 of 0.8, cells were methionine depleted in M9 medium containing 19 amino 
acids (no Met) for 15-45 minutes. Cells were then induced in M9 medium containing 19 
amino acids plus 40 mg/L azidohomoalanine with 0.5 mM IPTG for 2 – 4 hours. 
 Following peptide expression with AHA incorporation, cells were washed twice with 
cold phosphate-buffered saline (PBS) and reacted in PBS containing premixed copper 
and chelator (final reaction concentration of 100 μM CuSO4, 500 μM Tris(3-
hydroxypropyltriazolylmethyl)amine), 5 mM sodium ascorbate, and 300 μM bis-alkyne 
linker for 4 h at 4°C. Cells were then resuspended in 0.2% bovine serum album/PBS 
(PBS/BSA). 
 
Magnetic selections 
MDM2-GST-biotin for MACS was prepared as in ref. 27. 50 mL of bis-alkyne reacted cells 
were first labelled with 18 nM MDM2-GST-biotin in 0.2% PBS/BSA. Cells were then 
washed once with PBS/BSA and incubated with 500 uL MyOne C1 beads (Thermo 
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Fisher) for 25 min at 4 °C with gentle rotation using MACSmix (Miltenyi Biotec). Magnetic 
beads were pulled down by a DynaMag-5 magnet (Thermo Fisher) and washed gently 
with 5 mL PBS/BSA. Isolated bead-bound cells were miniprepped using a Qiagen 
miniprep kit according to ref. 27. Resulting DNA, generally 100-500 ng total, was 
transformed into fresh TYJV2 cells for additional sorting and analysis. 
Fluorescence selections 
For each linker library, 5 mL of cells were grown out, induced, and reacted as 
described above. Serial rounds of FACS were carried out with increasing stringency. The 
first round of sorting, cells were incubated with 4 nM MDM2-GST-AF647 (collecting 2% 
brightest cells), second round 1 nM (collecting 0.5% brightest cells) , and the third and 
fourth rounds incubated with 1 nM of MDM2-GST-AF647 first and then 30 nM MDM2-
GST-AF488 as described in ref. 27 to select for tight binders regardless of display level 
(roughly 1% of cells collected). Sorting was carried out in a MoFlo Astrios FACS 
instrument, and plasmids extracted and re-transformed into TYJV2 cells for further 
analysis and sorting if needed. 
 
Deep sequencing 
Plasmids were isolated from bacterial pellets by miniprep (Qiagen). Illumina Nextera XT 
sequencing primers were added to either side of the eCPX-peptide gene by PCR 
amplification using Q5 DNA polymerase (New England Biolabs). PCR products were 
cleaned by gel extraction and re-concentrated using a ZymoClean Clean & Concentrate 
kit. Another PCR amplification was performed also using Q5 to add the P5 and P7 Illumina 
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sequences for flow cell annealing as well as a unique 8 letter barcode on each end of the 
amplicon for demultiplexing. The second round of PCR was cleaned and re-concentrated 
identically. DNA concentrations were quantified using a QuBit fluorimeter, pooled, and 
submitted to the University of Michigan DNA Advanced Genomics core for analysis. 
Samples were demultiplexed by sorting samples with perfectly matched barcodes and 
ones that differed by up to one base pair. Samples were then analyzed with FastQC and 
samples with a PHRED score of less than 36 were discarded. Fastq files were then 
analyzed using Python scripts with Biopython and SeqIO packages. Forward and reverse 
reads were pairwise analyzed, discarding any sequences with differences in base pairs. 
The portion of the read that corresponds to the p53-based peptide was translated.  
 
Reaction efficiency 
To determine extent of reaction and stabilization, cells dually expressing p53-like 
sequence and HA tag were reacted as described above, washed, and further reacted in 
solution containing either 25 μM SCy5-alkyne or 25 uM Scy5.5-azide. Cell lysates, 
generated by boiling in SDS-PAGE loading buffer, were loaded onto a 4-12% Bis-Tris gel 
and run under denaturing conditions. The gel was transferred to a blot using the iBlot 
system (Invitrogen) and then probed for anti-HA signal to confirm even loading. Extent of 
reaction was quantified through normalization with the unreacted control and extent of 
stabilization determined through parameter fitting as described below: 
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The system of equations was adapted from Navaratna et al. 202027: 
 A, surface-displayed peptide; B, singly-reacted; C, stabilized peptide; D, two linker-reacted 
peptide; L, linker k' is rate of reaction of one site with L. k(, rate of stabilization d[A]dt = 	−k'[L] ∙ [A] d[B]dt = 	 k'[L] ∙ [A] − k([B] − k'[L] ∙ [B] d[C]dt = k([B] d[D]dt = k'[L] ∙ [B] 
All modeling was done in MATLAB R2018a. The parameters R1_new and 
ratio_rxn_new in the Supporting Information section “script for reaction rate and 
stabilization fraction analysis” represent k'	and <=<', the ratio of the second reaction rate to 
the first reaction rate respectively. R1_new and ratio_rxn_new were iteratively varied to 
match the relative reaction progress (from SCy5-alkyne quantitation) and relative SCy5.5-
azide signal, represented in the code out by completionnew and ratio_az_new 
respectively.  
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Supporting information 
 
MATLAB script for reaction rate and stabilization fraction analysis 
 
R1_PE = 1.8 %dimensionalless rate of first reaction for propargyl ether 
  
R1_new = 4.4 %dimensionless rate of first reaction for other molecule 
%this is iteratively fit to satisfy completionnew ratio_new and ratio_new 
  
ratio_PE = 3; %how much faster the second reaction is than the first for PE 
R2_PE = R1_PE*ratio_PE; %second reaction rate 
  
ratio_new = 0.0;  %how much faster the second reaction is than the first for other molecule 
%this is iteratively fit to satisfy completionnew and ratio_new   
  
R2_new = R1_new*ratio_new; 
simtime = 1; %dimensionless time 
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[azide_signalPE,completionPE] = stab_rxn_ODE(0.5,R1_PE,R2_PE,simtime); %scaled 
signal from SCy5.5-azide rxn, completion of AHA rxn 
[azide_signal_new,completionnew] = stab_rxn_ODE(0.5,R1_new,R2_new,simtime); 
  
azide_signalPE %this was iteratively fit to find rxn rates for propargyl ether 
completionPE 
  
azide_signal_new 
completionnew %this is output 1 and must match experiment 
  
ratio_new = azide_signal_new/azide_signalPE %ratio of azide signal of other molecule 
to azide signal from PE,  
%this is output 2 and must match experiment 
  
function [totalsignal,completion] = stab_rxn_ODE(L,r1,r2,simtime) 
  
close all; 
options = odeset('Maxstep',10); 
  
eqtime = [0, simtime]; %simulation length 
  
x=zeros(4,1); % 4 species  
%initialvalues: 
  
z0=100*45.15/105.88; 
x(1) = z0; 
  
x(2) = 0; 
x(3) = 0; 
x(4) = 0; 
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%{ 
 unreacted pep 
 single click 
 stabilized 
 two reacted pep 
%} 
  
L;%mM 
  
[T , X] = ode45(@(t, x)odesystem(t, x), eqtime, x,options); 
  
Time=T; 
  
plot(T,X(:,1)/z0,T,X(:,2)/z0,T,X(:,3)/z0,T,X(:,4)/z0) 
legend('unreacted','single click','stabilized','two reacted') 
  
frac_non_stab = r1*L/(r1*L + r2); 
%actual_frac_non_stab = X(length(T),4)/z0 
completion = 1 - (2*X(length(T),1) + X(length(T),2))/(2*z0); 
doublerxnsignal = 2*X(length(T),4)  ; 
totalsignal = 2*X(length(T),4)+X(length(T),2); 
  
frac_stab_total = 
X(length(T),3)/(X(length(T),1)+X(length(T),3)+X(length(T),2)+X(length(T),4)) 
frac_stab_rxn = X(length(T),3)/(X(length(T),3)+X(length(T),2)+X(length(T),4)) 
  
    function xdot = odesystem(t, x); 
    xdot = [-x(1)*L*r1 ;... 
            x(1)*L*r1 - x(2)*r2 - x(2)*L*r1;... 
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             x(2)*r2;... 
             x(2)*L*r1]; 
    end   
end 
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Chapter IV: A Tag-Free Two Color Approach to Sorting Displayed Libraries 
 
Tejas A. Navaratna and Greg M. Thurber 
 
Abstract 
Cell surface display and selection techniques have revolutionized therapeutic molecule 
discovery with their ability to screen diverse libraries in a high-throughput fashion. In the 
simplest fluorescence-based screens (e.g. FACS), the desired binding target is typically 
labelled with a fluorophore and incubated with the randomized cell population, after which 
the brightest cells are collected, re-screened, and/or sequenced. While straightforward, 
this approach suffers from lack of discrimination between high displayers and good 
binders. The bacterial display scaffold, eCPX, permits dual display of N- and C- terminal 
peptides and display normalization is reported, but in a peptide-specific manner. We have 
previously reported screening p53-like stapled peptides for MDM2 binding with bacterial 
surface display but found that steric clashes between the N-terminal p53 peptide and C-
terminal HA display tag were difficult to avoid and led to inconsistently decreased signal 
in both MDM2 and anti-HA channels. We report here a kinetic competition strategy 
between bound target of one color and a later-time same target of a second color. We 
conducted extensive modeling to determine important parameters, such as desired 
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dissociation constant (Kd), time between labelings, and final washout time. The resulting 
radial gating strategy, as computationally examined here will be used experimentally to 
isolate potent binders to various targets, including MDM2.  
 
Introduction 
Display techniques, including in phage, mRNA, bacteria, yeast, and mammalian cells 
have allowed the coupling of genotype to phenotype, and proteins with beneficial 
mutations can be selected and sequenced. Along with more general directed evolution 
techniques such as continual selection (e.g. PACE1), colony screens, growth rate 
competition in liquid media2, and organismal survival3, these methods have resulted in 
major advances in biomolecule design4–6. A confounding variable in protein design 
through directed evolution is the role of expression vs. molecular-level improvements. 
(However, it should be noted that sometimes selection of high expression is desirable, as 
mutations conferring high expression can be functionally equivalent to mutations 
conferring high activity for in-cell catalyst development7 or when there is correlation 
between expression level and protein thermal stability as reported in several examples in 
yeast surface display8). The increased expression vs. molecular improvement conflict 
occurs because protein sequence can affect expression level, through amino acid 
epistatic interactions leading to varying levels of folding or cell surface localization, or 
through codon usage differences leading to varied translation rates. In the case of 
directed evolution of affinity reagents (e.g. antibodies, antibody fragments, affibodies, 
etc.), surface display is a convenient way to couple genotype to binding potency for easy 
sequence decoding, but the end goal is typically to express or synthesize hit compounds 
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in solution to evaluate biological activity9–11. Thus, merely measuring level of target 
engagement on the cell surface can fail to discriminate between expression and activity, 
that is, a single-channel sorting scheme may fail to differentiate between an efficient 
displayer and a potent binder, and only selecting the brightest cells means losing out on 
poor displayers that are strong binders. 
Yeast surface methods have largely avoided this issue by using a separate display 
tag (typically c-myc) and labelling displayed proteins with a tag-specific fluorescent 
antibody in a different channel from the target protein12. Simultaneous detection of both 
signals allows discrimination based on display level and affinity, and an appropriate gating 
scheme can be drawn in FACS to select potent binders regardless of display level13. 
Wittrup and coworkers reported a 125-fold enrichment of a low-abundance mutant that 
had a modest 2-fold improved dissociation constant using an HA tag for measuring 
display level with yeast surface expression14. This was achieved with a single round of 
FACS at a low labeling concentration (0.25 nM) relative to the Kd (0.63 nM for the stronger 
binder vs. 1.37 nM). The labeling concentration was determined through a modeling 
analysis and was optimized by considering the signal-to-noise ratio in labeling and the 
relative Kd values of the desired strong binder vs. the background.  More recently, Keating 
and coworkers went further and developed a scheme to rank yeast-displayed peptides by 
dissociation constants based on their coordinates in a two-dimensional target vs. 
expression tag FACS plot15. Their approach combined multi-gate sorting with deep 
sequencing over a broad range of affinities to understand BH3 peptides’ binding to the 
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anti-apoptotic protein Bcl-xL and led to much better high-throughput assignments of 
affinity rankings than single-gate approaches.  
Bacterial surface display is uniquely suited for the expression of non-canonical 
amino acid-containing peptides. A met replacement strategy was highly successful in 
quantitatively incorporating azidohomoalanine (AHA) into outer membrane proteins16 and 
displayed scFvs17. Despite numerous other advantages for display, such as large library 
sizes and the potential of using continuous evolution1, phage display cannot be sorted 
with quantitative FACS and sorting is difficult to monitor while in progress. In comparison, 
yeast, while having lower library sizes due to lower transformability (typically 105-107 
members), can express a huge variety of proteins of sizes up to full antibodies12. This is 
suitable for large proteins, unlike E. coli and especially the eCPX scaffold, which is limited 
to the display of polypeptides of about 60 amino acids in length18. However, yeast is 
limited in its ability to incorporate the NCAAs required for most peptide stapling 
strategies19. We have previously developed SPEED (Stabilized Peptide Evolution by E. 
coli Display) to screen double click stapled peptides expressed with AHA incorporation 
using eCPX10.  The display level of peptides by eCPX can range over an order of 
magnitude, making deconvoluting expression and activity challenging18. Although eCPX 
is a biterminal display scaffold that theoretically permits simultaneous display and 
normalization, we and others have observed steric clashes manifesting in reduced 
binding kinetics by the affinity peptide when labeling both termini peptides 
simultaneously20. This can be partially ameliorated by increasing linker length between 
the peptide and scaffold, but in a sequence and length-dependent manner18. The highest 
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affinity peptide isolated, SPD-M6-V1, also had very high display levels, despite several 
rounds of FACS employing a similar two-color pseudo-expression-normalized strategy as 
described here. The efficient selection could be due to the higher expression or the 
improved binding affinity of this clone. To understand the quantitative mechanisms of 
affinity normalization by two-color labeling of the same peptide, we developed a 
computational system to test the effects of incubation times, target affinity, and 
concentrations on FACS discrimination. 
 
Results 
Modeling 
We hypothesized that by equilibrium labeling of the system with color 1 target, followed 
by kinetic labeling of the system with color 2 target, we could discriminate between tight 
binders that are low displayers and weak binders that are high displayers. Channel 1 
records signal from color 1 according to the fraction of displayed peptides bound to color 
1 based on its dissociation constant. This leads to coarse affinity and expression 
discrimination in the channel 1 axis (Figure III - 1). Addition of a high concentration (tight-
binder-saturating) of color 2 probe should result in increased signal in channel 2 primarily 
for peptides with a lower equilibrium occupancy of color1 target, i.e. high displayers and 
moderate binders (Figure III - 1). Thus, cells can be discriminated and selected based on 
both affinity and display level. To test this hypothesis, we wrote a script (see methods) to 
capture peptide occupancy by each color. 
  128 
 
Figure IV - 1. Schematic of affinity and expression discrimination scheme.  
Addition of color 1 target (blue triangles) and subsequent equilibration results in channel 
1 (x-axis) detection, shown schematically by a solid gate, leading to separation between 
high affinity high displayers and high affinity low displayers. However, moderate affinity 
high displayers are likely not to be efficiently distinguished from high affinity displayers 
with moderate display, resulting in false-positives. Addition of excess color 2 (red 
triangles) to bind to cells expressing low-to-moderate affinity peptides results in y-axis 
channel 2 discrimination. Weaker binders (that have more peptide not bound to color 1 
target) will bind to color 2 more efficiently due to its excess concentration, allowing for 
discrimination between moderate affinity high displayers and high affinity moderate 
displayers. The dashed line gate schematically represents the latter scheme. 
 
For computational analysis, we conducted our simulation as follows: 
 
Color1-target binds to displayed peptides and reaches an equilibrium fraction bound given 
by f?@ABC = [D@E@F'][D@E@F']G	HI , where [color1] is the concentration of color 1-target and Kd is the 
equilibrium dissociation constant. In an experimental system, equilibrium would be 
reached by incubation with color1-target for several hours. Calculation of fbound allows us 
to assign initial values for the peptide binding to color2-target differential equation system: 
 
Ch
an
ne
l 2
Channel 1
High affinity
High display
Moderate affinity
High display
High affinity
Low display
Low affinity
Low display High affinity
Moderate display
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1. C[AB?@ABC]CJ = −k@B	[unbound][color2] + k@SS	[bound1] + k@SS	[bound2] 
2. C[?@ABC']CJ = −k@SS	[bound1] 
3. C[?@ABC(]CJ = k@B	[unbound][color2] − k@SS	[bound2] 
 
Here, [unbound] represents the number of unbound peptides on the cell surface and is 
equal to (1 − f?@ABC) ∗ [peptide	expression] , where [peptide expression] is the display 
level. [peptide expression] can be a normalized or crude value, as flow cytometer signal 
in channels for color1 or color2 will be proportional to [bound1] or [bound2] respectively. k@B	and k@SS	are the kinetic parameters of binding, i.e, KC = <[\\	<[] 	. For this system, we 
assumed a typical k@B	 of 105 M-1s-1 and calculated k@SS	based on the KC. [bound1] and 
[bound2] are the number of peptides bound to color1-target or color2-target respectively. 
This system of ordinary differential equations captures unbinding of color1-target and 
color2-target, and binding of color2-target, but due to washing out of color1-target during 
color2-target incubation, we assumed color1-target association, i.e. rebinding, to be 
negligible due to the high concentration of competitor. 
 
Library flow cytometry simulations 
We first simulated flow cytometry plots for libraries containing a range of Kd values from 
500 pM to 10 nM and compared affinity and expression discrimination for one-color 
(Figure IV - 2A) and two-color schemes (Figure IV - 2B). This shows that a two color 
scheme can be used to successfully differentiate between high expressing moderate 
binders and low-to-moderate expression tight binders. 
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Figure IV - 2. Comparison of one-color and two-color sorting schemes.  
(A) a one-color workflow results in all peptides in one axis with decent separation between 
the poorest affinity binders (10 nM, yellow) and the high affinity binders (500 pM, blue). 
This is a result of low equilibrium binding and dissociation during the one-hour washout 
period. However, moderate affinity binders with high expression (large circles) overlap 
and even surpass signal from high affinity binders with low to moderate expression. (B) 
the two-color workflow developed here allows for robust affinity-expression 
discrimination. Cells with similar affinity but different expression appear as a line with 
increasing slope, signaling worse affinity. A gate (gray dashed line) can be drawn to 
separate higher affinity variants regardless of display level. 
 
Due to there being several free parameters in our system, that is, concentrations of 
color1-target and color2-target, library affinity range, receptor expression range, and 
importantly, time between color1-target washout and measurement, we first varied time 
to measurement (Figure IV - 3) to assess its importance. 
 
A B
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Figure IV - 3. Varying time of incubation with color2-target results in tunable sorting 
strategies.  
(A) For a very short 15-minute incubation time, color 2 signal is suppressed and less 
discrimination is observed between similar high affinity clones. A short incubation time 
may be beneficial if the Kd of even the best binders is greater than 5 nM. (B)-(D) increasing 
incubation time from 30 minutes to 2 hours results in maintenance of color1 signal for 
only the highest affinity binders, enabling a stringent sorting strategy. 
 
Experimental validation 
To experimentally validate these computational studies, we examined clones obtained 
from successive sorts of a click-stabilized p53-based randomized peptide library with 
affinity for MDM210. We have found a diverse collection of sequences with varying display 
levels and affinity (Table IV - I). Using the script detailed in the methods section, we 
simulated the expected coordinates for these sequences (Figure IV – 4) and included a 
A B
C D
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hypothetical sub-nM affinity binder (bottom right). These simulations suggest that the 
radial gated sort strategy, as elaborated above, would provide sufficient discrimination 
between affinity, regardless of display level.  
 
Figure IV - 4. Simulated flow cytometry coordinates of several sequences. 
Sequences were obtained by sorting a randomized library of stabilized peptides against 
MDM2. SPD-M0-E(-2) is the sequence closest to the native p53 sequence with small 
modifications and SPD-M6-V1 is the highest affinity candidate identified after one round 
of MACS and seven rounds of FACS, first detected by Sanger sequencing in round 6. as 
detailed in Chapter II10. 
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Table IV - I. Potential experimental sequences for validation from rounds of MACS 
and FACS against MDM2.  
SPD-M6-V1 is the highest affinity binder obtained from one round of MACS and 6 rounds 
of FACS, the number after the “M” refers to the sorting round. SPD-M0-E(-2) is the original 
p53-like sequence on which the library was based. WM is a weakly selectively round of 
MACS with 50 nM MDM2-GST-biotin incubation; SM is a stringent round of MACS with 2 
nM MDM2-GST-biotin incubation. Display levels were obtained from extrapolation in the 
limit of high concentration using a one-site binding model in Prism 8. Kd values were 
obtained with the same model using a titration of 6-12 logarithmically spaced MDM2-GST-
AF647 concentrations. 
 
Name Sequence Relative Display 
(Smax / Smax, SPD-M6-V1) 
Relative Affinity 
(Kd, SPD-M6-V1 / Kd ) 
SPD-M6-V1 VCDFXCYWNDLXGY 1.0 1.0 
SPD-M3-G1 GGTFXGYWADLXAF 1.5 0.54 
SPD-M3-V1 VLSFXDYWNLLXGS 1.5 0.38 
SPD-M0-E(-2)  ETFXDLWRLLXEN 0.57 0.09 
SPD-MWM-N1 NYDFXSGWVNLXCF 0.16 0.06 
SPD-M1-S1 SCGFXCVWDSLXSD 1.0 0.35 
SPD-MSM-Y1 YSCFXVYWCDLXGG 1.4 0.02 
 
Even a genetically homogeneous population of bacteria will show a range of binding 
signal, spanning roughly an order of magnitude (Figure IV – 5A). This is not only due to 
heterogeneity in peptide display but also likely due to channel location in flow cytometry, 
as bacteria are much smaller than eukaryotic cells and will not necessarily be forced into 
a single stream at the detection point. This results in binding histograms of roughly 
Gaussian shape, and the median fluorescence level can be quantified in used in assays 
(ie. affinity determination). This signal spread does lead to overlap in signals when binding 
affinity is sufficient (for example, SPD-M6-V1 and SPD-M0-E(-2) overlap somewhat in the 
upper range of SPD-M0E(-2) and lower range of SPD-M6-V1). Therefore, when sorting 
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complex library mixtures, a more stringent cutoff would provide finer discrimination among 
clones with similar affinity and/or display level. Variations in binding signal for cells 
displaying the same peptide is captured by the two-color analysis (Figure IV – 5B) and a 
similar radial gating strategy as presented in Figure IV – 3 can be used even considering 
the inherent variability of the system.  
 
 
Figure IV - 5. Analysis of clonal variability in one color and two color sorting.  
(A) Histograms of one color single clone binding (SPD-M6-V1 and SPD-M0-E(-2)) and 
bulk unsorted and sorted libraries as evaluated with bacterial surface display.  Figure 
adapted from Navaratna et al10. (B) The spread of signal for several example clones can 
be captured by varying the display level in simulations, and this simulation reveals that a 
radial gating scheme can be used even when considering expression variability. 
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Discussion 
This work represents a computational investigation of a tag-free method to normalize 
protein displayers based on expression level. We show that we can discriminate between 
clones of modest affinity differences regardless of display level (Figure IV – 2B, Figure IV 
– 4.). Dissociation plays an important role in discrimination, with the koff value controlling 
both the signal strength of the first color and the second (by allowing association). 
Therefore, control of time allowed for color 1 to dissociate (dissociation time, not to be 
confused with t1/2, off) was also varied in simulations (Figure IV – 3). Analysis of 
dissociation time revealed that this parameter affected sort stringency and provided 
guidance towards the design of sorting campaigns: namely, early rounds and rounds 
aimed at isolating moderate-affinity binders should be conducted with a short, 10 to 30-
minute-long dissociation time in order not to lose potential sequences that could be further 
affinity matured. Later rounds (or rounds known to contain high affinity, single digit nM Kd 
or better binders) should be conduct more stringently with longer dissociation times (1 to 
2 hours long).  
Additionally, we have chosen several candidate clones from sorting campaigns 
with a range of display level and affinity and these were modeled computationally, with 
the results showing that a radial gating strategy would be able to discriminate among 
binding affinities at varying display levels (Figure IV – 4, table IV – 1) 
We also considered histogram spread and expression variability within several 
example clones that could be a result of flow cytometric conditions or inherent cell-to-cell 
variability. We show computationally that a two-color sorting scheme allows for the design 
  136 
of gates that preserve clone selection regardless of cell or detection variability (Figure IV 
– 5). This platform therefore is a potentially powerful method of reducing noise and 
sampling bias in selections. Unlike variability in expression (length of r in Figure IV – 5B), 
affinity variability is more difficult to capture (variation in the angle θ in Figure IV – 5B) 
and work is ongoing to understand its impact on selections.  
The two-color sorting approach presented here could also be used in systems that 
are not amenable to tag-based normalization, such as difficult to engineer natural protein 
displayers (e.g. mammalian cells), including immune cell populations (displaying the T-
cell receptor and B-cell receptor) and MHC-peptide displayers. Future work will validate 
these computational methods to select specific clones based on affinity. 
 
Methods 
Clone selection 
Sorted libraries were plated at high dilution to obtain single colonies that were 
characterized for display level and binding affinity as described in ref. 10. Promising 
variants for future experimental validation by sorting were Sanger sequenced at the 
University of Michigan Advanced Genomics Core.  
 
Scripting 
All scripting was done in MATLAB 2018a.  
The annotated single .m file used to produce the plots in Figures IV - 2, IV - 3, IV - 4, and 
IV - 5B named dualcolorsort.m, is reproduced in its entirety below. 
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function dualcolorsort.m 
close all; 
  
kds = linspace(5e-10,10e-9,8); % affinity kd range in library (here, logspaced points 
between 500 pM and 10 nM) 
expression = linspace(1,12000,8); %expression range in library (here, evenly spaced 
points between 1 and 12000 peptides) 
time_at_measurement = 1; % time in hours after washing of 1st label and addition of 2 
label 
%time_at_measurement = logspace(-2,0.5,6);%hours, optional code if you 
  
second_labeling_conc = 100e-9; %concentration of second color label [M] 
first_labeling_conc = 10e-9;  %concentration of first color label [M] 
  
cmap = parula(length(kds)); %color scheme used to display points 
  
  
for times = 1:length(time_at_measurement) %if vector of time_at_measurement is given, 
this iterates through 
     
for i = 1:length(kds) %interation over kds 
    for j = 1:length(expression) %iteration over peptide expression  
    [T,X] = dual_color_label_embed(kds(i),expression(j),first_labeling_conc, 
time_at_measurement(times), second_labeling_conc); 
    sz = (20/length(expression))*j; %allows displayed data pointsize to scale with number 
of expression 
            hold all; 
             
%rest of this function is plot manipulation 
plot(X(length(T),2),X(length(T),3),'o','MarkerSize',sz,'Color',cmap(i,:)) 
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xlabel('First label signal (affinity), bound receptors') 
ylabel('Second label signal (display), bound receptors') 
set(gca,'FontSize',16) 
set(gca,'FontWeight','Bold') 
axis([0 max(expression) -500 max(expression)]) 
legendstring{j} = sprintf(' %s %0.1f ','Receptors = ',expression(j)); 
    end 
end 
delete(findall(gcf,'Tag','stream')); 
set(gcf,'position',[0,0,1200,700]) 
  
str = ['Time = ' num2str(time_at_measurement(times)) ' hrs, Second conc = ' 
num2str(1e9*second_labeling_conc) ' nM']; 
title(str,'Tag','stream'); 
A=reshape(legendstring,1,[]); 
  
legend(A, 'Location','northeast','FontSize',10) 
colormap(cmap); 
roundkds = round(kds,2,'significant'); 
kdlabels = string(roundkds); 
cbh=colorbar; 
 cbh.Ticks = linspace(0, 1, length(kds)) ; %Create 8 ticks from zero to 1 
 cbh.TickLabels = kdlabels ;    %Replace the labels of these 8 ticks with the numbers 1 to 
8 
 cbh.Label.String = 'Affinity Kd, nM'; 
set(gcf,'Position',[100 100 700 500]) 
end 
  
end 
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function [T,X] = dual_color_label_embed(k_d,receptor_count, first_labeling_conc, 
time_at_measurement, second_labeling_conc) 
  
k_on = 1e5; %M-1s-1 
k_off = k_d*k_on; %s-1 
  
number_bound = receptor_count * first_labeling_conc/(k_d + first_labeling_conc); 
%assumes equilibration of first labeling, standard because typically hours-overnight 
number_unbound = receptor_count - number_bound; %initializes the system for second 
binding diff eq 
  
eqtime = [0, time_at_measurement*3600]; 
options = odeset('Maxstep',10); 
  
x=zeros(3,1); % 3 species, peptide unbound, peptide bound with 1, peptide bound with 2 
%initialvalues: 
x(1) = number_unbound; 
x(2) = number_bound; 
x(3) = 0; 
  
[T,X] = ode23s(@(t, x)odesystem(t, x), eqtime, x,options); 
%ODE assumes 1 is lost when 2 is added (washing assumption, so 1 cannot 
%rebind the peptide) 
  
function xdot = odesystem(t,x) 
  
xdot = [-k_on*second_labeling_conc*x(1) + k_off*x(2) + k_off*x(3) ;... 
        -k_off*x(2);... 
        k_on*second_labeling_conc*x(1) - k_off*x(3)]; 
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end 
end 
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Chapter V: Concluding Remarks and Future Directions 
 
Summary 
This dissertation combines bio-orthogonal chemistry with non-natural amino acid 
incorporation to develop and apply a high-throughput method of engineering stapled 
alpha helical peptides. This bio-orthogonal chemistry, where the functional groups used 
do not cross-react with common biological chemical groups, enables cross-linking of non-
natural amino acids, while preserving the native functions of standard amino acids. 
Combining the high transformability of E. coli and its ability to incorporate a variety of non-
natural amino acids into induced proteins, we stabilized alpha helices on the surface of 
bacteria for directed evolution of semi-synthetic and chemically diverse biologically active 
molecules. 
 
Chapter I provides a background description of peptide engineering and the 
importance of stabilized alpha helices for the development of novel therapeutics. Chapter 
II details the method development using non-canonical amino acid (NCAA) incorporation 
into cell surface-displayed peptides, stabilization, and screening of libraries. In this novel 
approach, SPEED (Stabilized Peptide Evolution with E. coli Display), we displayed 
NCAA-incorporated peptides on the surface of methionine auxotrophic E. coli as fusions 
to a variant of the previously reported eCPX scaffold. We optimized display by using 
different promoter-vector systems and double-click stabilization reactivity through 
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modulating stabilizing linker concentration as well as testing various copper chelator and 
reducing agent concentration combinations. This resulted in successful click-stabilization 
of the majority of surface displayed peptides and we applied this to evolve high affinity 
inhibitors of the p53-MDM2 interaction, due to its dysregulation in many cancers. Starting 
with a p53-like variant, we went through one cycle of randomization and eight rounds of 
screening for binding to MDM2. This resulted in a nearly 10-fold improved binder (starting 
from an already improved sequence with Kd = 15 nM affinity) that contained an unusual 
disulfide bond in addition to the click-stabilized structural element, so we decided to 
conduct solution nuclear magnetic resonance (NMR) studies to better understand the 
peptide’s conformation. Together with MDM2-interaction transfer experiments, obtaining 
the solution structure led to new insights into helix preorganization for stapled peptide 
development. Specifically, even though disulfide bond appeared to mildly destabilize the 
alpha helix, the impact of the additional crosslink created a highly rigid peptide resulting 
in large affinity improvements.  
Chapter III discusses an extension of SPEED to evolve binders in the context of a 
stabilizing agent’s physicochemical properties. We found that a rigid staple, 1,3-
diethynylbenzene, does not react well to stabilize peptides on the cell surface. Despite 
this, we found binding improvements in all libraries tested, including a hydrophobic all-
hydrocarbon double-click staple, the aforementioned 1,3-diethynylbenzene, an amine-
functionalizable linker, and no linker at all. Most interestingly, the staple context mattered, 
with libraries evolved with one linker and reacted with a different linker generally showing 
diminished binding relative to reaction with the evolved linker. We show that a high affinity 
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propargyl ether-evolved peptide loses significant binding when stabilized with other 
linkers instead. This suggests that picking a linker due to its properties (such as protease 
stability, fluorescence, or cell penetration) cannot merely be an afterthought following 
sequence evolution. Rather, the evolution of randomized libraries ought to be carried out 
with each specific linker instead of relying on the notion of linker modularity not to diminish 
binding.  
In chapter IV, we describe the computational development of a tag-free expression 
normalization methodology for screening surface-displayed proteins. This was motivated 
by observed clashes between an anti-tag antibody and peptide-specific protein, leading 
to diminished signals in both channels. The eCPX scaffold is sluggish to display many 
highly charged tags and peptide display itself is highly sequence-dependent. This 
provided us with further impetus to develop a tag-free two-color fluorescence-based 
sorting strategy to screen libraries of surface displayed peptides. In summary, the library 
is incubated over hours (to reach binding equilibrium) with a limiting concentration of 
color1-target, after which it is washed and treated with a high concentration of color2-
target. We showed that this simple workflow enables discrimination between moderate 
affinity-high displayers and high affinity-moderate displayers, which is important when 
display is peptide-dependent. Finally, we chose peptides identified from previous screens 
that possess diverse display levels and binding affinity values for future experimental 
validation of this technique, which will include a comparison experiment between the one-
color, tag-free two-color, and display tag two-color methodologies to gauge efficiency in 
eliminating weak binders while enriching strong binders. 
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In Appendix I, we briefly discuss chemical synthesis, purification, and NMR 
characterization of the amine-functionalizable linker used in Chapter III. Appendix II 
details the alanine-scanning experiments for the p53-like sequence that informed the 
randomization strategy used in Chapter II. We elaborate in Appendix III on our attempts 
to sort for binders against other targets, specifically, the intracellular proteins KRAS and 
NOTCH1 as well as the extracellular CD8 protein. Finally, in Appendix IV, we discuss the 
engineering of double-click stabilized two-helix bundles for the molecular imaging of Her2.  
 
Future directions 
This dissertation is largely devoted to the development of methods for the screening of 
stabilized peptides. The applications for these techniques include development of 
chemical biology tools to understand cellular interactions, for novel therapeutic therapy, 
and for affinity-based bioseparations. 
 Still, there are many areas for potential improvement in this research. Although 
one round of randomization and extensive screening for MDM2 binding resulted in 
discovery of a potent Kd = 1.8 nM binder (SPD-M6-V1), additional re-diversification and 
selections can possibly improve affinity, particularly given the theoretical diversity of the 
original NNC library being 3.8 x 1010 sequences and our first library consisting of only 3 x 
108 members. In reports, multiple rounds of randomization have been carried out for the 
discovery of strong binders from naïve libraries1. Most of this past work has used yeast 
and re-randomization is especially useful when library sizes are smaller. This is because 
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even a modest number of randomized sites results in an intractably large number of 
sequences to test with current display systems. For example, there are 4 x 1010 possible 
sequences for a peptide with 9 randomized amino acids and capturing this diversity 
requires a minimum of 1011 transformants for sufficient coverage. This is near the upper 
limit of bacterial techniques2 and to the best of my knowledge, has not been accomplished 
in methionine auxotrophic cells. Because our original scheme encoded 9 randomized 
amino acids and we achieved a transformation yield of 3 x 108 clones3, we screened no 
more than 1% of possible sequences. Our alanine scan results (Appendix II) indicate that 
many amino acids tolerate substitution to alanine, which is evidence that the well of affinity 
is broad at the high affinity limit (there are likely many sequences that resemble SPD-M6-
V1 that are equally potent binders). This is consistent with a report of solid phase peptide 
sequence modifications of MDM2 binders, where Partridge et al. found that single-residue 
substitutions of ATSP-7041 generally preserved high binding affinity4. To ensure that 
SPD-M6-V1 is representative of the most potent binding series of peptides discoverable 
by our SPEED technique, we have re-randomized an SPD-M6-V1-based sequence with 
NNN codons to encode any amino acid. This will inevitably encode undesired stop codons 
(premature termination) and methionine codons (inappropriate stabilization sites), but as 
this randomization is based on the already affinity-improved SPD-M6-V1, we hope that 
truncated sequences will be rapidly screened out.  
Furthermore, we observed significant differences in display level for peptides of 
the same length (p53-like peptides, Chapter IV) and for peptides against other targets, 
such as KRAS and NOTCH1. We hypothesize that the highly charged nature of the 
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putative NOTCH1 binder did not allow for correct folding and translocation to the outer 
membrane. Because of these differences in display are inevitably present in the original 
randomized libraries and we did several one-color sorting rounds (including MACS) prior 
to implementing two color sorting, it is possible that we lost high affinity, low displaying 
binders early in the sorting workflow. This is an additional motivation for SPD-M6-V1 
rerandomization and in the longer term, may benefit from other display strategies 
including in a yeast system. Additionally, while stabilization improved the correlation 
between affinities measured on the bacterial membrane and in solution, the two values 
diverged significantly in a small number of sequences (Chapter II). For example, SPD-
M0-E(0) showed rather poor affinity in solution (Kd = 74 nM) but moderate affinity on the 
bacterial surface (Kd = 12 nM). Aga2-displayed peptides on yeast have better correlation 
between surface and solution binding5,6, and we hypothesize that this is due to the greater 
distance away from the cell compared to eCPX (and potential for bacterial LPS to induce 
crowding, affinity-modifying effects at the surface). There have been strides made 
recently in NCAA incorporation in yeast7 but additional strain and protein engineering may 
be necessary to achieve the near-complete NCAA replacement required for high fidelity 
stabilized peptide display. 
Machine learning is another powerful avenue for designing better proteins. There 
have been several reported and impressive applications of machine learning to protein 
engineering, including the design of antimicrobial peptides and designer enzymes. Armed 
with flow cytometric data from thousands of clones (including binding isotherms from 
dozens of sequences) and next-generation sequencing data, we are starting to 
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understand evolutionary trends applied to several targets. I have great hope that in the 
years to come, deep learning with rich datasets will enable us to fill in the sequence and 
chemistry gaps that even the largest experimental peptide libraries are unable to meet, 
to design peptides that not only bind with high affinity but are also able to rapidly enter 
the cell and resist degradation.  
 As discussed previously, we have good reason to believe that there are a large 
number of chemically diverse SPD-M6-V1-based high affinity sequences. The NMR 
structure and docking (Chapter II) of SPD-M6-V1 showed that many side chains are not 
involved in significant inter- or intramolecular bonding, consistent with reported crystal 
structures of p53 and p53 analogues. This suggests that SPD-M6-V1 may be amenable 
to single site substitutions. While affinity is important for stapled peptide activity, 
intracellular delivery is generally considered to the roadblock in efficient modulation of 
protein-protein interactions8. In this dissertation, we discovered a high affinity MDM2 
binder and further work can elucidate sequence-penetration relationships through single 
and multiple-site mutation to cationic or lipophilic amino acids without serious affinity loss. 
As shown by cell-surface affinity measurements and structural analysis, the disulfide bond 
of SPD-M6-V1 is important for high affinity binding. The intracellular environment is a 
reducing environment and we do not yet understand the stability of this specific disulfide 
bond in the presence of glutathione. Many protein toxins contain a rich network of disulfide 
bonds, with some being inert to cytosolic reducing conditions. Disulfide bonding as well 
as organized secondary structures are well appreciated to reduce protease degradation 
and we have found that protease resistance correlates well with in vitro anti-cancer 
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activity. Deep sequencing and re-randomization of the SPD-M6-V1 peptide can reveal 
peptides with similar binding properties but diverse protease stability, amphiphilicity, and 
therefore potentially cellular permeability. Exploration of this space will allow discovery of 
profound connections among sequence, structure, and function.  
 Finally, there are many more interesting targets to explore using SPEED. Immune 
checkpoint inhibitors against PD-1, PDL-1, and CTLA-4 have made tremendous strides 
in the oncology landscape, but these therapies come with serious side effects making it 
imperative that patients are chosen accurately. Identification of these receptors in tumors 
involves invasive biopsies9 and high temporal resolution of receptor response to therapy 
(e.g. loss-of-expression mutations) is challenging to achieve. A tight binding peptide-
based imaging agent (through NIR or MRI modalities) would bind in an expression-
dependent manner and quickly clear, reducing contrast10. Such peptides also have 
possibilities in intraoperative imaging to identify tumor margins and metastases.  
 This work would not have been possible without major developments in chemistry 
and biology. Efforts to introduce non-canonical amino acids into proteins, combined with 
advances in stapled peptide development led us to develop a new technique to rapidly 
screen libraries against virtually any disease protein-protein interaction. This has led to 
the discovery of unusual disulfide bonded and double-clicked peptides that are potent 
binders of MDM2. There are efforts underway to understand the translatability of such 
molecules for cancer inhibition. I hope that expansion of this method to other targets will 
be highly fruitful and improve the drug and molecular imaging agent landscapes.  
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Appendices 
 
Appendix I: Synthesis and Characterization of a Functionalizable Stabilizing 
Linker 
In Zhang et al. 2015 and Zhang et al. 2016, we developed and applied a bifunctional bis-
alkyne containing linker to staple exendin-4 for imaging and protease stability 
characterization. We present directed evolution results with this linker in Chapter III of this 
thesis. The molecule was synthesized as follows: N-Boc-2,2′-
(ethylenedioxy)diethylamine (805 μmol) was added to diisopropylethylamine (2.40 mmol) 
in 3.8 mL MeCN. Propargyl bromide in toluene was added dropwise (2.62 mmol). The 
reaction mixture was stirred overnight at room temperature before being concentrated 
under reduced pressure and then subjected to flash chromatography (80:7:1 CHCl3: 
MeOH: NH4OH). The desired fraction was concentrated, deprotected using 50% 
trifluoroacetic acid in dichloromethane, and purified using preparative RP-HPLC using a 
linear gradient of MeCN in H2O to yield 1 (475 μmol, 59%).1H NMR (400 MHz, CD3OD) 
δ 3.89 (4H, d), 3.77 (2H, t), 3.73 (2H, t), 3.70 (4H, s), 3.18 (2H, t), 3.15 (2H, t), 3.04 (2H, 
t). 13C NMR (400 MHz, CD3OD) δ 76.8, 74.6, 69.9, 69.8, 66.5, 51.9, 42.2, 39.2. HRMS: 
m/z calculated for C12H20N2O2: 225.1603, found: 225.1600. 
Reproduced with permission from Zhang, Navaratna, Liao, and Thurber. Bioconjug. 
Chem. 2016, 27 (7), 1663–1672. Copyright 2020 American Chemical Society.  
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Appendix II: Alanine Scanning Mutagenesis of p53-Like Peptide 
Prior to directed evolution experiments to discover potent inhibitors of MDM2 (Chapter II), 
we individually mutated each residue of a native p53-like sequence (ETFXDLWRLLXEN) 
to alanine using the primers in table A1, the template pQE80L-eCPX2-PLP from 
Navaratna et al.1. The protocol for point mutagenesis was adapted from ref. 2 and 
transformed into met auxotrophic TYJV2 E. coli for expression.  
In this alanine scanning approach, we kept the stabilization sites fixed, and 
measured binding affinity in the context of bacterial surface display to evaluate the 
feasibility of the method and to inform the selection of residues to randomize for screening 
studies. Representative binding isotherms are shown in Figure A1. 
 
 
Table A - 1. List of primers used in this alanine scanning study of a p53-like peptide. 
 
Mutation Sequence 
E17A TCCGTAGCTGGCCAGTCTGGCCAGGCAACCTTTATGGATCTGTGGC
GCCTGC  
T18A GTAGCTGGCCAGTCTGGCCAGGAAGCCTTTATGGATCTGTGGCGC
CTGCTGATG 
F19A GCTGGCCAGTCTGGCCAGGAAACCGCTATGGATCTGTGGCGCCTG
CTGAT 
D21A GGCCAGTCTGGCCAGGAAACCTTTATGGCTCTGTGGCGCCTGCTGA
TGGAAAAC  
L22A GGCCAGTCTGGCCAGGAAACCTTTATGGATGCGTGGCGCCTGCTG
ATGGAAAAC 
W23A GCCAGTCTGGCCAGGAAACCTTTATGGATCTGGCGCGCCTGCTGAT
GGAAAACGGCGGT 
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R24A AGTCTGGCCAGGAAACCTTTATGGATCTGTGGGCCCTGCTGATGGA
AAACGGCGGTGGCA  
L25A GGCCAGGAAACCTTTATGGATCTGTGGCGCGCGCTGATGGAAAAC
GGCGGTGGCA  
L26A CAGGAAACCTTTATGGATCTGTGGCGCCTGGCGATGGAAAACGGC
GGTGGCAGCGGA  
E28A ACCTTTATGGATCTGTGGCGCCTGCTGATGGCAAACGGCGGTGGCA
GCGGAGGGCAGT  
N29A GGATCTGTGGCGCCTGCTGATGGAAGCCGGCGGTGGCAGCGGAG
GGCAGTCT 
 
 
Figure A1. Several binding isotherms for p53-like sequence (WT) and single-aa 
alanine substituted mutants.  
Of measurable alanine substituted constructs (F19A and W23A had no detectable signal), 
L26A had the lowest affinity, consistent with the binding structure and computational 
alanine scanning results.  
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Figure A2. Comparison of experimental and computational alanine scans. 
Bacterial surface alanine scanning (sdMet) was compared with molecular mechanics 
approaches3 and statistical approaches4 as validation for surface display of p53-like 
peptides. We were unable to measure binding signal for F19A and W23 mutants and thus 
report >10000 relative Kd for these constructs.  
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Appendix III: Sorting Campaigns Against Other Targets 
We have also attempted to engineer potent stapled peptide binders to several other 
targets including the intracellular KRAS and NOTCH1 proteins and the extracellular 
portion of CD8. Recombinant expression of all three proteins was successful, but initial 
screens did not show convincing evidence of binding to KRAS and NOTCH1 for 
sequences reported in the literature. A very recent report by Ng and coworkers found that 
the reported all-hydrocarbon stapled SOS1-based sequence5 did not exhibit KRAS-
specific binding6, consistent with our findings. As there were no reported peptide binders 
to CD8 at the beginning of the project, we constructed a naïve library and conducted 
several rounds of MACS and FACS to attempt to discovery consensus binding 
sequences. Because of anticipated weak affinity from a naïve library, a CD8 tetramer 
target was generated to boost avidity. Unfortunately, we did not observe significant 
binding to fluorescent CD8 and to tetramerized CD8 in our sorted populations.  
 
KRAS 
We based our double-click peptide sequence on the hydrocarbon stapled peptide mimic 
of SOS1 with sequence FFGIMLTNILKMEEGN5 and cloned it into eCPX using the 
forward primer SOS1pep and reverse primer pQE80L rev. An HA sequence C-terminal 
of SOS1pep was inserted using SOS1pep-HA fwd and SOS1pep-HA rev for display 
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characterization. Soluble KRAS2B was produced as a GST fusion from Addgene plasmid 
#55655 (a gift from Julian Downward), Figure A4. Displayed SOS1pep showed 
significantly decreased display compared with p53-like peptide (Figure A5), but still was 
detectable above background. We did not detect KRAS-GST binding to SOS1pep (Figure 
A3) even with the addition of nucleotide triphosphates which can modulate the KRAS-
SOS1 interaction5 
 
 
Figure A3. Flow cytometric analysis of peptide binding against various targets.  
P53-like sequence does not exhibit any binding to KRAS, as expected, but was included 
as positive control for binding to MDM2. SOS1pep does not exhibit binding to KRAS with 
and without the presence of 1 mM dNTPs at the concentrations tested (400 nM KRAS2B-
GST).  
 
NOTCH1 
We based our double click peptide sequence on the hydrocarbon stapled peptide mimic 
of MAML with sequence ERLRRRIMLCRRHHMT7 and cloned it into eCPX using the 
forward primer MAMLpep and reverse primer pQE80L rev. An HA sequence was inserted 
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C-terminal of MAMLpep using a similar SOE PCR strategy as for SOS1pep. Soluble GST-
N1IC was produced from Addgene plasmid #47612 (a gift from Urban Lendahl), Figure 
A4. MAMLpep did not display to significant levels over background and non-induced 
controls (Figure A5), and we hypothesize that is due to the highly charged (5 arginine 
residues) nature of the peptide. It has been observed that the display of highly charged 
sequences is suppressed in bacterial outer membrane systems8. 
 
 
Figure A4. Reducing, denaturing SDS-PAGE gel of purified KRAS2B-GST, MDM2-
GST, and Notch1ICD-GST.  
All three have been labeled with AlexaFluor647 using nonspecific lysine chemistry. The 
gel was visualized on a Licor Odyssey NIR scanner. 
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Figure A5. Detection of HA tag C-terminal of several peptides by flow cytometry. 
This revealed undetectable display for MAMLpep and diminished display of SOS1pep 
relative to the p53-like sequence for various induction times. 
 
 
CD8 
We expressed CD8a using procedures adapted from ref. 9 with the expression plasmid 
as a gift from K. Natarajan. The homodimer was purified in moderate yield from inclusion 
bodies after refolding (Figure A6).  
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Figure A6. Reducing, denaturing SDS-PAGE gel of cells and purified recombinant 
CD8a. 
 
A naïve 15-mer peptide library was generated using the naïve library fwd primer and 
pQE80L rev for screening to CD8 with two i,i+7 methionine sites fixed for click stabilization 
at sites 5 and 12. A library size of 2 x 109 members was generated according to the 
procedure described by Getz and Daugherty10, but sequencing revealed that 
approximately 30% of these were non-peptide expressing eCPX plasmid background. 
Since we expected little interaction between eCPX and CD8, we were able to monitor 
fraction of non-peptide expressing clones to gauge sorting efficiency and success.  
After 4 serial rounds of MACS with biotinylated CD8a and 1 round of FACS with AF647-
labelled CD8a, we saw no change in the abundance of non-peptide expression clones 
and concluded that a larger search space needs to be accessed to find binders. 
Alternative approaches could include CD8 multimerization to increase the avidity of 
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surface-displayed peptide-CD8a interactions to pull out initially weak binders. This would 
be followed by affinity maturation through re-randomization and further screening. 
 
Table A - 2. Primers used to display putative KRAS and NOTCH complex binding 
peptides and variants. 
SOS1pep ACTTCCGTAGCTGGCCAGTCTGGCCAGTTTTTCGGCATTATGCTGA
CCAACATCCTGAAAATGGAAGAAGGTAATGGCGGTGGCAGCGGAG
GGCAGTCTGGGCAGTCTG 
MAMLpep ACTTCCGTAGCTGGCCAGTCTGGCCAGGAACGCCTGCGCCGCCGC
ATTATGCTGTGCCGCCGCCATCATATGACCGGAGGGCAGTCTGGG
CAGTCTGGTGACTACAACAAAAACCAG 
pQE80L 
rev 
GAGGTCATTACTGGATCTATCAACAGGAGTCCAAGCTCAGC 
SOS1pep-
HA fwd 
TATCCGTACGATGTGCCGGATTATGCGGGAGGGCAGTCTGGGCAG
TCT 
SOS1pep-
HA rev 
CGCATAATCCGGCACATCATACGGATAGCTGCCACCGCCATTACCT
TCTTCCATTTTCAG 
Naïve 
library fwd 
ACTTCCGTAGCTGGCCAGTCTGGCCAG 
NNCNNCNNCNNCATGNNCNNCNNCNNCNNCNNCATGNNCNNCNNC 
GGCGGTGGCAGCGGAGGGCAGTCTGGGCAGTCTG 
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Appendix IV: Double-Click Stapled Two-Helix Bundles for Imaging Her2 
The discovery of new cancer targets and a more detailed understanding of their 
contributions to cancer increases each year, but challenges remain in converting these 
scientific gains to clinically relevant therapeutic and imaging applications. Specifically, the 
HER2 gene has been implicated in many aggressive forms of breast cancer, as well as 
in some stomach and ovarian cancers. The overexpression of this gene results in 
promotion of proliferation and inhibition of apoptosis. As such, it has been an important 
target for drug discovery, and two monoclonal antibodies, trastuzumab and pertuzumab, 
have been developed for treatment of HER2-positive breast cancer. There is a clinical 
need to rapidly diagnose and monitor tumor response to treatment. Existing antibody-
based HER2 binders take on the order of hours to days to target tumors and clear from 
healthy tissues, making them impractical as imaging agents11. Importantly, probe 
localization is independent of expression level, making these large molecules unsuitable 
for quantitatively imaging expression to determine the feasibility of treatment with a Her2 
directed therapy. Orlova and colleagues developed a three-helix bundle containing ~7 
kDa affibody that bound to Her2 with a 22 pM Kd and used it for radioimaging12. Because 
of ease of synthesis, handling, and potentially better pharmacokinetics, Webster and 
colleagues evolved a two-helix variant but were not able to recapitulate the high affinity 
of the three-helix affibody13. We have used bio-orthogonal chemistry to stabilize the 
secondary structure of a 35-amino acid sequence two-helix bundle. The method we have 
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developed allows facile attachment of a fluorophore or radiolabel for imaging applications. 
These molecules exhibit greater helicity than the original molecule, with concomitant 
increase in binding affinity to HER2 by three to four-fold. 
Based on the crystal structure reported by Eigenbrot and colleagues of the three 
helix affibody bound to Her2 (Figure A7)14, we rationally selected stabilization sites to 
avoid locations that would (1) remove intramolecular hydrogen bonding, (2) remove 
binding interactions with Her2, (3) remove hydrophilicity (to ensure solubility), or (4) 
introduce potential steric clashes especially upon stabilization with a bulky fluorophore. 
Thus, we selected sites 3-10 and 21-28 on helices 1 and 2 respectively to introduce 
azidohomoalanine residues to permit click stabilization (Figure A7). 
 
 
Figure A7. Crystal structure of the three-helix bundle bound to Her2 (PDB ID 
3MZW).  
The third helix, which is on the viewer’s side of the structure, was removed for visual 
clarity. Residues E3 and E10 on the first helix are shown in red and Q21 and S28 on the 
second helix are shown in blue. 
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We obtained helix 1 (H1), helix 2 (H2), and single AHA (S1) variants of ZHer2 from 
Innopep (San Diego, CA). 
 
Table A - 3. Sequences of 2-helix bundles tested. 
 Z = homocysteine, X = azidohomoalanine. The termini are disulfide bonded together. 
 
Name Amino acid sequence 
Helix 1 (H1) ZNKXMRNRYWXAALDPNLNNQQKRAKIRSIYDDPZ 
Helix 2 (H2) ZNKXMRNRYWEAALDPNLNNQQKRAKIRSIYDDPZ 
Single AHA (S1) ZNKEMRNRYWEAALDPNLNNQXKRAKIRXIYDDPZ 
 
Imaging extracellular receptors with near-infrared (NIR) dyes allows for deeper imaging 
than shorter wavelength fluorophores and offers advantages over other imaging 
techniques as well, including its non-ionizing nature, good contrast, and low cost15. 
Choice of dye matters: dyes with different physicochemical properties can affect 
clearance, cell residualization, and binding affinity16,17. We synthesized a panel of dye 
and helix variants (sequences in Table A - 1, dye structures in Figure A8) and 
characterized the affinity and helicity of select few variants. Products were purified by 
HPLC in high purity (representative MALDI spectra shown in Figure A9). 
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Figure A8. Chemical structures of four near-infrared (NIR) dyes used in this study.  
(A) Cyanine5.5 (Cy5.5), (B) DDAO (C) SulfoCyanine5 (SCy5) (D) AlexaFluor680 (AF680) 
 
 
 
Figure A9. Reflectron positive MALDI spectra for H1 and H1-SCy5. 
 
We first tested alpha helical character for non-stabilized and SCy5-stabilized versions of 
H1, given that pre-organization and increased helicity decreases the entropic cost of 
N N
O
NH
N
OHO
Cl
Cl
O
NH
N N
O
NH
-O3S SO3-
H
N
SO3-
N
SO3-
N
N
Br
SO3-
O
A B
C D
H1-SCy5H1
Expected: 4273.6
Found: 4271.0
Expected: 5120.9
Found: 5119.2
  165 
binding and therefore can increase binding affinity18–20. SCy5-H1 was made by adapting 
the procedure developed by Zhang et al.19 by first conjugating amine-reactive NHS ester 
dye to the functionalizable linker and then click-stabilizing the two-helix bundle in solution. 
We observed a modest increase in helicity from 22% to 38% (Figure A10).  
 
 
Figure A10. Circular dichroism spectrograms of H1 and H1 stabilized with SCy5. 
We observed improved alpha helicity values for the stabilized bundle (22% vs 38% 
helical), determined from molar ellipticity at 222 nm values. 
 
To see if increased preorganization by stabilization translated to affinity improvements, 
we titrated H1-SCy5 against the Her2 overexpressing human gastric cancer NCI-N87 cell 
line (ATCC) and indeed observed increase in affinity from 12 nM to 2.8 nM. We also 
tested H2-SCy5 but there was no significant improvement in affinity (10 nM). Binding 
isotherms are shown in figure A11. 
H1
H1-SCy5
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Figure A11. Titrations of fluorescent probes against Her2 on NCI-N87 cells. 
(A) H1-Scy5 (B) H2-SCy5, and (C) non-stabilized S1-SCy5. 
 
We tested the impact of dye physicochemical properties on Her2 binding using the four 
dyes Cy5.5, DDAO, SCy5, and AF680 (Figure A12). Cy5.5 is a bulky, hydrophobic dye 
with a +2 net charge, DDAO is relatively small and neutral, while SCy5 and AF680 share 
structural characteristics including size and negative charge. We synthesized helix 1 
stabilized variants with all four dyes and observed significantly worse binding for Cy5.5 
than the other 3 (Kd = 39 nM for Cy5.5, 2.1 nM for DDAO, 7.6 nM for AF680 (figure A12), 
and 2.8 nM for SCy5 (figure A11) ).  
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Figure A12. Titrations of NIR fluorophore-H1 stabilized bundles against Her2 
expressed on NCI-N87 cells.  
DDAO-conjugated bundles (A) were observed to have the lowest Kd, whereas Cy5.5 (B) 
showed relatively poor binding.  
 
Finally, based on literature reports of protein functionalization through cysteine bridging 
via maleimide chemistry21, we reacted and generated maleimide-bridged H1 (H1-mal) 
and double-click stabilized this to generate H1-mal-SCy5. Direct labeling of NCI-N87 cells 
with H1-mal-SCy5 revealed a much-reduced affinity of 67 nM (Figure A13, left) and to 
verify that this loss of binding was not a result of the click stabilization, we conducted a 
competition binding assay with known binder S1-SCy5 (Kd = 12.2 nM) to determine an 
further reduced affinity (Kd value of 93 nM, Figure A13, right). Stabilization, for maleimide-
bridged two-helix bundles, appears to restore some affinity, but not close to the affinity of 
the original disulfide-bridged proteins. 
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Figure A13. Titration experiments for maleimide-bridged H1. 
Affinities were calculated with (direct binding, left) and without (competition, right) click 
stabilization. 
 
Conclusions and future directions: This work combined rationally designing 
stabilization sites with peptide modification strategies to engineer high affinity imaging 
agents of Her2. It is apparent from these data that dye and stabilization location have 
outsized impacts of binding affinity, with DDAO and SCy5 providing the tightest binding, 
and helix 1 proving to the better location for stabilization. Future work will involve 
expanding this approach to other dye/linker combinations to generate even higher affinity 
binders, and in vivo imaging of Her2 expressing tumors to determine if Her2 
downregulation in cancer resistance development can be imaged and to gauge 
chemotherapy response over time.  
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